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Until today, PDAC is characterized by its extremely high mortality rate and the lack of
effective treatment strategies despite reinforced focus on the elucidation of underlying
molecular mechanisms in the last decades. The development of novel chemotherapeutic
treatment strategies remains a challenge due to its extraordinary heterogeneity with re-
gards to genetic alterations, stromal composition, and tumor cell metabolism. Patient
stratification according to molecular subtyping is a promising strategy to efficiently
target PDAC in a precision medicine-based approach. Molecular taxonomy aims to ex-
ploit specific cancer vulnerabilities to increase chemotherapeutic response and prolong
the life expectancy of patients.
In this work, we focused on the large genetic subgroup of SMAD4-deficient PDAC in
the context of oncogenic KRAS activation, comprising 55 % of patients. With the help
of GEMMs, we aimed to comprehend features of Smad4-depleted PDAC in vivo and
elucidate synergisms in Kras and TGFβ signaling. This is complemented by in vitro
studies, opposing Smad4 WT PDAC cells to their respective CRISPR/Cas9-generated
Smad4-depleted counterparts. We disclosed induced migratory potential and stemness
characteristics as well as increased tolerance to the nucleoside analog Gemcitabine upon
loss of Smad4. In contrast, Smad4-depleted PDAC cells demonstrated extraordinary
sensitivity towards Mek inhibition by Trametinib.
The TGFβ pathway is strongly intertwined with NFATc1 signaling, an inflammatory
transcription factor pivotal for PDAC evolution. We scrutinized the role of NFATc1
in hijacking Smad3-dependent transcription in favor of oncogenic gene signatures in
Smad4 deficiency. Cooperativity studies illuminated direct interplay of NFATc1 and
Smad3 transcription factors and conditions permitting or abrogating their nuclear com-
plex formation. With the identification of cJun as a third transcription factor involved
in the nuclear complex, we gained a window of opportunity to target the transcription
complex by disrupting its assembly with Trametinib. Genome-wide expression studies
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revealed potential targets of the NFATc1/Smad3/cJun complex and disclosed tran-
scriptional induction of genes associated with improved PDAC patient survival and
increased Gemcitabine response upon complex disruption by Trametinib.
Thus, on the one hand, we suggest a mechanism how Smad4-depleted cells evade
Gemcitabine-induced cytotoxicity by NFATc1/Smad3/cJun-mediated transcription. On
the other hand, we propose a strategy on how to interfere with the transcription factor
assembly by effective Mek inhibition mediated by Trametinib, thus restoring Gemci-
tabine sensitivity in the context of Smad4 deficiency. Together, these data provide a
potential novel chemotherapeutic treatment regime with combinatorial Trametinib and
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Pancreatic cancer is a highly lethal disease that is projected to become the second lead-
ing cause of cancer-related death in the United States of America (USA) and Germany
by 2030 (Rahib et al., 2014; Quante et al., 2016). Its dismal prognosis is substantiated
by late diagnosis due to unspecific symptoms, pronounced plasticity, extreme hetero-
geneity, and strong resistance to chemotherapeutic treatment (Adamska et al., 2017;
Siegel et al., 2018). The 5 year survival of 8 % covers all stages of the disease and
represents the lowest score in cancer statistics of the USA (Siegel et al., 2018). Despite
reinforced elucidation of molecular mechanisms driving pancreatic ductal adenocarci-
noma (PDAC) formation and progression, there is still no breakthrough in advanced
cancer therapies. Due to exceptional genetic heterogeneity, PDAC research is now
focusing on patient stratification to offer customized therapeutic approaches for molec-
ular subtypes of this dreadful disease.
1.1 PDAC heterogeneity: chance and pitfall
The most prevalent variant of pancreatic cancer accounting for 90 % of patient cases
originates from the exocrine gland and is termed PDAC (Biankin et al., 2012). Hahn
& Kern (1995) first identified Kirsten rat sarcoma (KRAS) as a crucial enhancer of
PDAC formation and progression. In over 90 % of invasive PDAC, activating mutations
of the KRAS protooncogene are described, predominantly mediated by G12D transition
(Hingorani et al., 2003; Bryant et al., 2014). Constitutively activated KRAS provokes
sustained stimulation of downstream signaling effectors, leading to increased prolifer-
ation, suppression of apoptosis, altered metabolism, evasion of immune response, al-
terations in composition of tumor microenvironment, and metastasis (Pylayeva-Gupta









PanIN1a/b PanIN2 PanIN3 PDAC
Figure 1 PDAC arises from preneoplastic lesions. The exocrine part of the
pancreas is composed of acinar cells having the potential to undergo
ductal reprogramming and thus giving rise to PanIN lesions. PanINs are
graded with respect to nuclear atypia and loss of cell polarity into four
stages. Robust desmoplastic response accompanying PanIN progression
is a hallmark of PDAC. Modified from Morris et al. (2010).
PDAC originates from preneoplastic lesions [Figure 1] that are formed in regenerative
response to inflammatory insults like acinar-to-ductal metaplasia (ADM) or due to
tumor-promoting mutations like oncogenic activation of Kras in pancreatic intraep-
ithelial neoplasias (PanINs) (De La O et al., 2008; Reichert & Rustgi, 2011). The term
ADM describes an early precancerous lesion originating from the acinar compartment
of the pancreas undergoing a potentially reversible transdifferentiation into ductal cells
(Reichert & Rustgi, 2011). Importantly, ADM potentially evolves into PanIN lesions
and thereby lose their regenerative capacity (Song et al., 1999; Means et al., 2005; Zhu
et al., 2007). Upon their degree of dysplasia, PanIN lesions are categorized into four
stages: PanIN1a, PanIN1b, PanIN2, and PanIN3. While PanIN1a starts with minimal
morphological alterations, the grade of nuclear atypia and loss of cell polarity increases
during PanIN progression towards carcinoma in situ at PanIN3 stage complemented by
pleomorphism and nuclear enlargement (Hingorani et al., 2003; Ottenhof et al., 2011).
However, although PanIN lesions have the potential to develop into carcinoma, their
progression is limited and needs further trigger factors besides oncogenic Kras activa-
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tion to form full-blown, invasive PDAC. Morris et al. (2010) summarized pancreatic
carcinogenesis being dependent on accumulative mutations, loss of tumor suppressor
genes, a chronic inflammatory environment, and the activation of oncogenic pathways.
Multiple studies demonstrated that oncogenic Kras activation is necessary for PDAC
formation, but not sufficient to drive its further development (Hingorani et al., 2005;
Guerra et al., 2007; Ardito et al., 2012; di Magliano & Logsdon, 2013). Besides onco-
genic Kras activation, there are a few frequent mutations occurring in PDAC concern-
ing CDKN2A inactivation (encoding for the tumor suppressors p16INK4a and p19ARF),
TP53 mutation potentially leading to gain-of-function of the respective p53 protein,
and loss of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4.
However, Jones et al. (2008) identified an average of 63 genetic alterations in human
PDAC, accentuating the vast extent of PDAC heterogeneity. Importantly, PDAC di-
versity is further enhanced by alterations in the tumor microenvironment like immune
cell invasion/evasion and extracellular matrix (ECM) composition as well as tumor cell
metabolism, respectively (Carr & Fernandez-Zapico, 2016; Ying et al., 2016).
Molecular taxonomy of PDAC based on high-throughput genomic and transcriptomic
analyses aims to define patient subgroups for precision medicine-based therapeutic im-
plications (Singh et al., 2019). The first attempt of molecular subtyping in PDAC
was realized by Collisson et al. (2011), identifying three epithelial subtypes. Moffitt
et al. (2015) partly confirmed their data by dissecting two epithelial and two stromal
subtypes, respectively. Based on the identification of four epithelial subtypes by Bailey
et al. (2016), Maurer et al. (2019) lately reanalyzed patient cohorts and determined in
agreement with Moffitt et al. (2015) the classical and basal-like epithelial tumor cell
subtypes as well as immune-rich (normal) and ECM-rich (activated) stroma. Eventu-
ally, PDAC patient stratification according to their molecular subtypes not only offers
prognostic value but also aims at enhancing therapy response.
To the present day, pancreatic surgery remains the only potentially curative treatment
option for PDAC. However, its application is limited due to late diagnosis in advanced
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disease stages and early metastatic spread (Adamska et al., 2017). Since 1997, unre-
sectable PDAC is treated with Gemcitabine (2’,2’-difluoro 2’-deoxycytidine or dFdC),
a nucleoside analog that is still in use for metastatic pancreatic cancer in patients with
low performance status (Burris et al., 1997; Ellenrieder et al., 2016). As PDAC is highly
refractory to systemic therapies, clinical studies aim at complementing Gemcitabine-
based chemotherapy with additional drugs to convey higher specificity and improve
patient outcome (Kleeff et al., 2016). In terms of palliative treatment, nano-formulated
albumin-bound paclitaxel combined with Gemcitabine emerged as a more effective al-
ternative to Gemcitabine monotherapy (Von Hoff et al., 2013). FOLFIRINOX (a com-
bination of oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) is the most promising
treatment option with significant improvement of life expectancy, but severe side effects
restrict its applicability to patients with good performance status (Conroy et al., 2011).
Interestingly, Aung et al. (2018) demonstrated that the classical epithelial tumor cell
type is associated with good response to first-line chemotherapy, while the basal-like
type poorly responded to treatment. Consequently, PDAC patient stratification can
offer insights into potential chemotherapeutic responses, elucidating elevated chemore-
sistance or chemosensitivity towards specific drug combinations that only develop their
full potential in one specific subtype. Thus, future precision medicine approaches aim
at connecting molecular data from PDAC specimen with intrinsic chemotherapeutic
vulnerabilities in order to offer the most promising treatment option to the correspond-
ing patient subgroup.
1.2 NFATc1 as an inflammatory driver of pancreatic
carcinogenesis
One hallmark of PDAC is the establishment of a chronic inflammatory environment,
both favoring cancer formation and progression (Morris et al., 2010). Since Buchholz
et al. (2006) introduced the nuclear factor of activated T cells (NFAT) family of inflam-
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matory transcription factors as crucial drivers of PDAC progression, NFAT research
has been focusing on scrutinizing the role of respective family members in shaping the
transcriptional output of pancreatic cells (Baumgart et al., 2012; Awla et al., 2012;
Baumgart et al., 2014; Hessmann et al., 2016). Of the five NFAT family members,
nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) plays an outstanding role
in providing growth advantage, apoptosis evasion and dedifferentiation to PDAC cells
(Baumgart et al., 2014; Chen et al., 2015; Singh et al., 2015; Chen et al., 2017; Has-
selluhn et al., in revision). Thus, promotion of NFATc1 signaling during pancreatic
carcinogenesis complements oncogenic Kras activation in driving PDAC progression
and metastasis.
The activation of NFAT family members is mediated by the Ca2+/calcineurin signaling
pathway (Clipstone & Crabtree, 1992). Resting highly phosphorylated in the cytoplasm
in their inactivated state, NFAT transcription factors can be activated by diverse signal-
ing pathways causing influx of intracellular calcium ions. High calcium concentrations
activate calcineurin, which in turn dephosphorylates multiple phosphoserines on NFAT
proteins, thereby demasking the nuclear localization sequence (NLS) resulting in nu-
clear shuttling (Loh et al., 1996; Shibasaki et al., 1996; Garcia-Cozar et al., 1998). In
the nucleus, NFAT transcription factors share the consensus site 5’-GGAAA-3’ which
is preferably located in promoter/enhancer regions of many immune response and pro-
liferation genes (Buchholz et al., 2006). Continuous calcineurin activity is required for
sustained NFAT nuclear localization as constitutively active kinases target NFAT for
rephosphorylation and subsequent transfer out of the nucleus (Neal & Clipstone, 2001;
Sheridan et al., 2002). Importantly, it is known that NFAT proteins regulate gene
transcription insufficiently alone, therefore they rather form complexes with additional
transcription factors (Loh et al., 1996; Chen et al., 1998; Baumgart et al., 2014). The
transcriptional output of NFAT proteins is highly dynamic and context-dependent and
thus can be shaped via respective binding partners.
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For the investigation of NFATc1-dependent processes in PDAC development, Baum-
gart et al. (2014) developed the cnNFATc1; KrasG12D; p48-Cre (NKC p48) mouse
model. Constitutive nuclear NFATc1 signal in the context of oncogenic Kras activa-
tion dramatically accelerates PanIN formation and progression towards PDAC in this
genetically engineered mouse model (GEMM) (Baumgart et al., 2014; Hasselluhn et al.,
in revision). In contrast, pancreas-specific loss of NFATc1 (NFATc1fl/fl;KrasG12D) de-
celerates preneoplastic lesion formation and PDAC establishment compared to NFATc1
wildtype (WT) mice despite oncogenic Kras activation (Baumgart et al., 2014; Chen
et al., 2015; Hasselluhn et al., in revision). Additionally, NFATc1 as a malignant pro-
moter of PDAC was highlighted by Singh et al. (2015), demonstrating that NFATc1-
mediated transcription cooperates with mutation of the tumor suppressor Tp53 in
driving PDAC dedifferentiation and metastasis. These findings are in agreement with
Diaferia et al. (2016) linking strong NFATc1 expression to high-grade PDAC in human
tissue.
1.3 TGFβ signaling in PDAC: a double-edged sword
Robust desmoplastic response in collaboration with immune cell infiltration is one
crucial driver of tumor growth, disease progression and drug resistance (Kalluri &
Zeisberg, 2006; Aran et al., 2015). As the stromal compartment comprises up to 90 %
of the tumor burden in PDAC (Neesse et al., 2011), understanding of the interaction
between epithelial tumor cells and the tumor stroma is crucial for the development of
effective cancer treatment strategies. The interplay between diverse cell types in PDAC
is based on a multitude of secreted signaling molecules of which transforming growth
factor beta (TGFβ) is one of the most abundant and complex mediators. TGFβ is
produced and released by fibroblasts, endothelial cells, macrophages, and lymphocytes




1.3.1 Canonical and non-canonical TGFβ pathway
According to their ligands, the TGFβ family subdivides into TGFβ, Activin, and
bone morphogenetic protein (BMP) subfamilies (Heldin et al., 1997) [Figure 2 A]. The
TGFβ group is unique in its receptors (TGFβ receptor-I/II (TβR-I/II)) but shares
downstream Smad proteins with the Activin group (Heldin et al., 1997). Smad2 and
Smad3 proteins are activated upon receptor-mediated phosphorylation and form com-
plexes with the common-Smad (Smad4) prior to translocation to the nucleus and sub-
sequent activation of transcription (Eppert et al., 1996; Zhang et al., 1996; Nakao et al.,
1997b). In contrast, BMP signaling is mediated by receptor-phosphorylation of Smad1,
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Figure 2 Canonical and non-canonical TGFβ signaling. A The TGFβ su-
perfamily comprises Activin, BMP, and TGFβ canonical signaling cas-
cades according to their respective ligand. The common SMAD binding
partner SMAD4 and the inhibitory SMADs (SMAD6/7) act through-
out the superfamily. B Non-canonical TGFβ signaling is mediated via
receptor activation but the exact way of signal transduction to effector
proteins remains elusive. Only the best-characterized targets are shown.




regulation (Attisano & Wrana, 2000). The inhibitory Smads (Smad6 and Smad7, re-
spectively) exert their function throughout the TGFβ family and disrupt signaling
by binding to type I receptors, interfering with phosphorylation of pathway-restricted
Smads (Imamura et al., 1997; Nakao et al., 1997a). As the transcription of inhibitory
Smads is induced by TGFβ itself, Heldin et al. (1997) suggest inhibitory Smads act-
ing as autoregulatory negative feedback loops in the signal transduction of the TGFβ
superfamily. In addition, the non-canonical TGFβ signaling comprises the activation
of the Ras signaling cascade (Derynck & Zhang, 2003).
Despite their significant homology in sequence and structure, Smad2 and Smad3 exert
fundamentally different functional roles in TGFβ signaling (Yang et al., 2003). Accord-
ing to studies in mouse embryonic fibroblasts by Yang et al. (2003), Smad3 deficiency
completely blocks TGFβ response. In contrast to Smad2, Smad3 and Smad4 directly
bind DNA at the palindromic sequence 5’-GTCTAGAC-3’ known as the Smad binding
element (SBE) (Zawel et al., 1998). Smad3 primarily activates transcriptional regula-
tors to initiate a cascade of secondary gene regulation (Yang et al., 2003). Importantly,
TGFβ-regulated intermediate-early genes are highly cell type-dependent (Yang et al.,
2003) which is in agreement with the strong role of Smad binding partners in defining
target gene and pathway specificity as well as the transcriptional effect (Massagué et al.,
2005). For sufficient TGFβ activation, several SBE copies are required while binding
variability is mediated by positions outside the SBE (Zawel et al., 1998). Due to its
known synergism with the RAS cascade and activator protein 1 (AP-1) transcription
factors, de Caestecker et al. (2000) propose SMAD3 as a key mediator of oncogenic
TGFβ signaling.
The TGFβ family of cytokines is responsible for a plethora of developmental and
homeostatic processes as it unites a multitude of different signaling cascades that can
be dysregulated in disease. Cellular responses include initiation of cell cycle arrest,
apoptosis, differentiation, cell motility, extracellular matrix production, angiogenesis,
and cellular immune response (Zawel et al., 1998; Derynck & Zhang, 2003). In early
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disease stages and in healthy tissue, TGFβ acts as a tumor suppressor by exerting
antimitogenic effects (Heldin et al., 1997) mediated by Cyclin-dependent kinases (Mat-
suura et al., 2004) in addition to promotion of cytostasis or apoptosis (Massagué, 2008).
However, during cancer development, cells acquire resistance towards the growth in-
hibiting functions of TGFβ and exploit its full potential in a tumor-promoting manner
(Massagué, 2008; Ikushima & Miyazono, 2010). Accordingly, detected levels of TGFβ
in carcinomas exceed those observed in corresponding healthy tissue by far (Pardali &
Moustakas, 2007). Importantly, altered TGFβ signaling is one hallmark of PDAC, in-
cluding the dysregulation of both canonical and non-canonical pathway (Bailey et al.,
2016). Oncogenic TGFβ actions comprise fundamental changes in stroma composi-
tion, evasion of immune response, angiogenesis, and tumor cell invasiveness (Pardali &
Moustakas, 2007).
Until now, the contextual mechanism how the switch from tumor-suppressive to tumor-
promoting TGFβ signaling is conveyed is still a matter of debate. For pancreatic can-
cer, the critical involvement of Krüppel-like factor 10 (KLF10), NFATc1, and SMAD4,
have been discussed in the context of oncogenic KRAS activation (Mishra et al., 2017;
Singh et al., 2010; Zhang et al., 1997). SMAD4 deletion concerns 55 % of all patients,
characterizing it as one of the most frequent genetic events in PDAC (Hahn et al.,
1996a,b; Wilentz et al., 2000a). Homozygous inactivation of both alleles results in
complete loss of function (Schutte et al., 1996), thus featuring aggressive PDAC and
metastasis formation in patients (Shin et al., 2017). Importantly, SMAD4 deficiency
occurs at the stage of established PDAC, while its expression levels remain intact dur-
ing PanIN progression (Wilentz et al., 2000a; Hosoda et al., 2017). As there is no
progressive reduction of SMAD4 expression, immunohistochemistry (IHC) serves as an
excellent tool to detect SMAD4 deactivation, regardless of its inactivation mechanism
(Wilentz et al., 2000a). Loss of Smad4 is associated with TGFβ-mediated epithelial-
mesenchymal transition (EMT), a well-coordinated process during embryonic devel-
opment and wound healing which turns to a pathological feature in neoplasia and
fibrosis (Duda et al., 2003; Thiery, 2003; Subramanian et al., 2004; Massagué, 2008).
9
1 Introduction
Cells undergoing EMT gradually lose expression of epithelial cell junctions in favor of
a more mesenchymal cytoskeleton leading to increased cell motility (Massagué, 2008)
and resistance to growth inhibition by TGFβ (Oft et al., 1996). In addition, Jazag
et al. (2005) associated Smad4 depletion in PDAC with decreased cell adhesion and
increased cell motility. Thus, induction of EMT by loss of Smad4 contributes to tu-
mor progression and metastasis formation by promoting invasion and dissemination of
motile cancer cells (Mani et al., 2008).
TGFβ utilizes various intracellular signaling pathways in addition to SMADs to reg-
ulate a wide array of cellular functions via non-canonical signaling (Zhang, 2009)
[Figure 2 B]. By direct ligand-occupied receptor activation, the TGFβ signaling cas-
cade interacts with a multitude of mitogen-activated protein kinases (MAPKs) such
as extracellular signal-regulated kinase (ERK), cJun N-terminal kinase (JNK) and p38
kinases (Hartsough & Mulder, 1995; Engel et al., 1999; Hanafusa et al., 1999; Ho-
cevar et al., 1999; Sano et al., 1999; Bhowmick et al., 2001; Yu et al., 2002; Zhang,
2009). Yang et al. (2003) demonstrated that ERK function is required for efficient
activation of a certain gene set, while other genes depend on ERK inactivation to be
susceptible for TGFβ-induced regulation. Importantly, it was evidenced that ERK
signaling enhances SMAD3-dependent gene activation by positive interaction with ac-
tivated SMADs (de Caestecker et al., 1998; Zhang et al., 1998). JNK and p38 have been
implicated in TGFβ-induced apoptosis, EMT, cell motility, and cancer cell invasion
(Bhowmick et al., 2001; Yu et al., 2002). Therefore, the broad spectrum of regulated
genes in combination with its huge potential to interact with additional pathways and
its role in mediating signals from tumor to stromal cells establishes TGFβ pathway as
one of the most important signaling cascades in PDAC.
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1.3.2 Cooperativity of NFAT and TGFβ signaling cascades
NFATc1 does not only exert its oncogenic potential in the epithelial tumor cells, but
establishes an inflammatory microenvironment promoting further tumor progression
(Baumgart et al., 2014). Singh et al. (2010) demonstrated that NFATc1 signaling is
closely linked to TGFβ activation as TGFβ induces NFATc1 expression and activation
as a mechanism to overcome TGFβ-mediated growth arrest. However, in the setting
of constitutively active NFATc1 signaling, TGFβ counteracts NFATc1-mediated pro-
liferation and apoptosis evasion (Hasselluhn et al., in revision). The strong PDAC
plasticity and interconnection of a plethora of signaling pathways result in a high de-
gree of context dependency emphasizing the need to comprehend underlying molecular
patterns to successfully counteract oncogenic gene signatures.
As both SMAD3 and NFAT transcription factors are implicated in shaping the tumor
microenvironment, functional cooperativity of both transcription factors was investi-
gated in diverse cellular systems (Tone et al., 2008; Singh et al., 2010; Tardif et al.,
2013; Sengupta et al., 2013; Mokrani et al., 2014). First, NFAT and Smad3 coopera-
tivity was described in immune cells. Tone et al. (2008) identified SMAD3 cooperating
with NFAT at the FOXP3 enhancer and mediate histone acetylation with subsequent
FOXP3 protein induction in T regulatory cells. In addition, Mokrani et al. (2014)
showed SMAD2/3 and NFAT1 coregulation of CD103 expression on T lymphocytes
contributing to cytotoxic t cell response and cancer cell destruction. In contrast, Tardif
et al. (2013) demonstrated micro RNA-140 (miR-140) regulation by NFAT3 as a tran-
scriptional activator as opposed to SMAD3 repressor activity. This interplay is in
agreement with Singh et al. (2010), elucidating NFAT competing with SMAD3 in reg-
ulation of MYC protooncogene in PDAC. On a functional level, Sengupta et al. (2013)
identified NFAT silencing as efficient inhibitor of TGFβ-mediated EMT in breast can-
cer and suggested NFAT/SMAD3 complex formation. However, direct transcription
complex formation of NFAT and SMAD proteins has not been shown in any cellular
system yet and thus remains a matter of investigation.
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1.4 Mechanisms behind Kras-driven PDAC
Oncogenic Kras activation occurs in over 90 % of PDAC patients, making it the most
prominent driving force in pancreatic carcinogenesis initiation (Hingorani et al., 2003).
Kras belongs to the family of Ras proteins that share approximately 80 % sequence ho-
mology and are distinguished by their carboxy-terminal hypervariable regions (Nussi-
nov et al., 2015). Ras proteins are ubiquitously expressed and involved in the regulation
of cell proliferation, differentiation, survival, migration, and apoptosis (Nussinov et al.,
2015). They bind guanosine triphosphate (GTP) and anchor in the membrane for their
activation and subsequent signaling (Nussinov et al., 2017). In turn, GTPase-activating
protein mediates GTP to guanosine diphosphate (GDP) hydrolysis, a process that is
reversible by exchanging GDP by GTP with the help of guanine nucleotide exchange
factor (Nussinov et al., 2017). Importantly, for oncogenic Ras, steric hindrance impedes
with hydrolysis of GTP by GTPase-activating protein, thus resulting in constitutive
Ras signaling independent of extracellular activation signals (Schlichting et al., 1990;
Scheffzek et al., 1997; Wittinghofer & Vetter, 2011).
However, the complex and dynamic Kras signaling cascades are still not entirely
understood. Nussinov et al. (2015) elucidate oncogenic Kras signaling, disclosing
strong redundancy of pathways, temporality of cell decisions and variation of pre-
ferred signaling cascades in different tumor entities. In PDAC, there are four ma-
jor pathways involved: RAF/mitogen-activated protein kinase kinase (MEK)/ERK,
phosphatidylinositol 3 kinase (PI3K)/3-phosphoinositide-dependent protein kinase 1
(PDK1)/RAC-alpha serine/threonine-protein kinase (AKT), JNK, and guanine nu-
cleotide exchange factor (Lim et al., 2005; Feldmann et al., 2010; Collisson et al.,
2012; Eser et al., 2013, 2014; Davies et al., 2014). While Eser et al. (2013) and Eser
et al. (2014) highlighted the pivotal role of PI3K/PDK1/AKT cascade for ADM and
PanIN formation as well as PDAC establishment, Collisson et al. (2012) described
RAF/MEK/ERK signaling as a driver of neoplastic alterations, indicating that both
pathways are crucial in PDAC initiation and development. In contrast, impaired JNK
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signaling in the context of oncogenic KRAS activation was associated with accelera-
tion of PDAC progression and reduced regenerative capacity of acini (Davies et al.,
2014). Meanwhile, Lim et al. (2006) and Vigil et al. (2010) discovered strong activa-
tion of guanine nucleotide exchange factors in PDAC. However, it remains unclear how
oncogenic Kras activation signals to preferred context-dependent downstream cascades
during carcinogenesis and how the complex network interacts.
An important nuclear target of the RAF/MEK/ERK cascade is the transcription fac-
tor family AP-1 (Johnson et al., 1996). Lamph et al. (1988) and Johnson et al. (1996)
described AP-1 activation relying on the same stimuli as ERKs, including oncogenic
RAS and growth factors. The AP-1 family comprises heterodimers and homodimers of
JUN, FOS, MAF and ATF transcription factors known for their crucial role in medi-
ating cell proliferation, survival and cell death (Ryseck et al., 1988; Shaulian & Karin,
2001). One crucial mediator of the JUN transcription factors is cJUN (Bohmann et al.,
1987), whose homozygous depletion leads to severe impairment of AP-1 transcriptional
response and prevents transformation by RAS (Johnson et al., 1996). Importantly,
cJUN activity is controlled by JNK-mediated phosphorylation and dominant negative
cJUN alleles lacking the JNK phosphorylation sites impede with RAS transformation
(Lloyd et al., 1991; Smeal et al., 1991). Conversely, RAS activation triggers cJUN
expression, promotes AP-1 binding activity and thus determines its full oncogenic po-
tential (Johnson et al., 1996). In contrast, Johnson et al. (1996) demonstrated that
mutated RAS does not signal through induction of JUNB and JUND, respectively, thus
highlighting the particular importance of cJUN as a downstream effector of oncogenic
RAS activation.
Kras signaling is strongly intertwined with the TGFβ signaling pathway. First of all,
Oft et al. (1996) demonstrated RAS mutation promoting TGFβ mRNA and protein
expression in mammary epithelial cancer cells. In this autocrine manner, constant acti-
vation of the TGFβ cascade is ensured. Importantly, RAS-transformed cells lose capac-
ity to respond to TGFβ with growth arrest (Kretzschmar et al., 1999; Sekimoto et al.,
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2007), resulting in diminished tumor-suppressive TGFβ activity without abrogation
of TGFβ responsiveness. In contrast, cells may respond with invasive and metastatic
behavior (EMT) instead (Kretzschmar et al., 1999). This alteration in downstream
regulated gene signature can be mediated via SMAD3 linker domain phosphorylation
by KRAS-driven MAPKs such as ERK, JNK, and p38 (Kretzschmar et al., 1999; Fu-
rukawa et al., 2003; Mori et al., 2004; Sekimoto et al., 2007). This is in agreement with
altered TGFβ responsiveness in RAS-transformed cells (Sekimoto et al., 2007; Hassel-
luhn et al., in revision), presenting tumor-promoting TGFβ signaling as a functional
collaboration of oncogenic RAS activation and SMAD proteins. Interestingly, the AP-1
complex integrates signaling from both TGFβ and MAPK pathways (Liberati et al.,
1999). Moreover, KRAS mutation interferes with SMAD4-dependent senescence induc-
tion by TGFβ, thus making loss of SMAD4 superfluous for early PanIN development
(Fullerton et al., 2015). However, Leung et al. (2013) claim that malignant transfor-
mation of normal ductal pancreas cells requires KRAS mutation and loss of SMAD4
to overcome TGFβ-mediated growth arrest. In the context of SMAD4 deficiency in
PDAC, oncogenic KRAS and activated TGFβ signaling synergize in driving oncogenic
gene signatures to their full potential.
1.5 Aims of the study
PDAC is a highly lethal disease characterized by high metastatic spread, chemoresis-
tance, and its huge genetic heterogeneity. The most prominent genetic alteration is the
oncogenic activation of Kras in 90 % of all PDAC patients, initiating early preneoplas-
tic lesion formation in the pancreas which eventually develops into carcinoma stage.
Loss of Smad4 is a frequent event in established PDAC (55 %) and is of predictive
value concerning metastasis formation, thus making it an extensively studied subject
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Figure 3 NFATc1 as an alternative Smad3 binding partner in Smad4-
deficient PDAC. Loss of Smad4 is a frequent event in PDAC pro-
gression and a known mediator of the switch from tumor-suppressive to
oncogenic gene signatures. We hereby propose that alternative aggres-
sive gene signatures are enforced by NFATc1/Smad3 transcription com-
plexes, exploiting tumor-promoting signatures in TGFβ-driven PDAC.
Smad4 is a crucial part of the TGFβ signaling cascade, mediating the translocation of
activated receptor Smads into the nucleus. However, in the absence of Smad4, TGFβ
signaling is not abrogated, but comprises alternative signaling pathways resulting in
the activation of differential transcription programs. Loss of Smad4 is implicated in
driving oncogenic TGFβ signatures towards more invasive and aggressive PDAC. How-
ever, the exact mechanism how Smad3-mediated transcription in the context of Smad4
deficiency is hijacked in the direction of tumor-promoting gene transcription remains
elusive. Here, we aim to study the mechanistic and functional consequences of Smad4
deficiency in PDAC on oncogenic Smad3 transcription complex formation and gene
transcription. We focus our study on NFATc1, an inflammatory transcription factor
implicated in PDAC development and progression. Previous work from our labora-
tory already suggested functional cooperativity between Smad3 and NFATc1, which is
further exploited in this project.
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We hereby propose that the formation of NFATc1/Smad3 transcription complexes is
required for TGFβ-promoted cancer cell plasticity in a Smad4-deficient PDAC subtype
[Figure 3]. Based on this hypothesis, this study aims to (i) determine if NFATc1 is an
alternative Smad3 binding partner in Smad4-depleted PDAC, (ii) elucidate permissive
conditions for proposed transcription complex assembly, (iii) identify gene signatures
regulated by NFATc1/Smad3 complexes, and (iv) develop a strategy on how to disrupt
respective transcription complexes in favor of reestablishment of tumor-suppressive
TGFβ signaling. By combining in vivo and in vitro approaches, we aim to scrutinize
whether targeting of potential NFATc1/Smad3 complexes overcomes tumor-progressive
functions of Smad4 deficiency and therefore represents a promising pharmacological
strategy to tackle Smad4-depleted PDAC.
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2 Material and Methods
In this chapter, material and methods are described which were crucial in data acqui-
sition and analysis for this thesis. However, some studies were conducted as part of
cooperations, so detailed protocols are not described here. Dr. med. H. Bohnenberger,
Institute of Pathology, University Medical Center Göttingen provided human tissue
microarrays (TMAs), assisting in staining and analysis. Moreover, he enhanced our
tumor studies by offering Masson’s trichrome staining for tumor-bearing mice. In the
meantime, tumor grading of respective PDAC-bearing mice was kindly conducted by
Prof. P. Ströbel, Institute of Pathology, University Medical Center Göttingen. In an
exchange with Prof. S. Hahn, Clinical Research Center, Ruhr-Universität Bochum and
Prof. J. Siveke, West German Cancer Center, University Hospital Essen, we retrieved
primary human PDAC cells gathered from patient-derived xenograft (PDX) studies.
Sequencing of respective PDX-derived cells was conducted by Prof. B. Wollnik and
PD Dr. rer. nat. S. Kaulfuß, Department of Human Genetics, University Medical
Center Göttingen. Additionally, Dr. S. Nagarajan, Cambridge Research Institute,
University of Cambridge, enhanced our studies by comparison of published chromatin
immunoprecipitation sequencing (ChIPseq) data.
Graphs were visualized using GraphPad Prism (version 8.0.1). Data are presented as
mean ± standard deviation. Significance was tested by Student’s t-test if not stated
otherwise, presenting significance as * p < 0.05, ** p < 0.01, and *** p < 0.001,
respectively.
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2.1 Cell culture
2.1.1 PDAC cells and cultivation
A variation of PDAC cell lines was used to comprehend Smad4-dependent processes
in vitro. NKC-II cells are primary murine PDAC cells derived from a tumor-bearing
cnNFATc1; KrasG12D; p48-Cre (NKC p48) mice. Its establishment is described by
Baumgart et al. (2014). Accordingly, murine KPC Bl6 cells are derived from the cor-
responding KrasG12D; p53R172C/+; pdx-Cre mouse model and were gifted by PD Dr.
Dr. med. A. Neeße. Importantly, KPC mice were bred with a pure C57BL/6 back-
ground making this cell line applicable for orthotopic transplantation experiments in
C57BL/6-J mice. Sequencing of TP53 locus conducted by L. Versemann, Department
of Gastroenterology and Gastrointestinal Oncology, University Medical Center Göttin-
gen, dissected the R172C transition instead of the expected R172H alteration. Clones
derived from NKC-II or KPC Bl6 cells were cultivated in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco, 41 965-62) supplemented with 10 % fetal bovine serum (FBS)
(Biowest, S181B-500) and 1 % non-essential amino acids (NEAA). In contrast, human
cell lines PaTu8988t and Bo62 were maintained in DMEM supplemented with 10 %
FBS. Human BxPC3 cells are grown in Roswell Park Memorial Institute (RPMI)
(Thermo Fisher, 61 870 044) enriched with 10 % FBS and 1 % L-Glutamine.
In general, cells were cultivated at 37 ◦C and 5 % CO2 until they reached 90 % conflu-
ency. For subcultivation, the medium was removed, cells were washed with phosphate
buffered saline (PBS) followed by trypsinization (Gibco, 15 400-54; 1:10 dilution in
PBS). Trypsinization was stopped by adding cultivation medium and cells were seeded
according to the respective experiments.
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2.1.2 Treatment and transfection
Cells were allowed to attach overnight (o/n) prior to further treatment. For TGFβ
(PeproTech, 100-21B, 10 ng/ml) and a selection of Trametinib (Biomol, Cay16 292-50)
studies, cells were serum-starved in their respective medium for 24 h prior to treat-
ment for 24 h. 1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene (UO126)
(Calbiochem, 662 005) was added for 24 h in normal cultivation medium. In contrast,
studies with Gemcitabine-Hydrochloride (Sigma-Aldrich, G6423) were incubated for
either 48 h or 72 h and cytosine arabinoside (AraC) for 72 h (Sigma-Aldrich, C1768).
As Trametinib and UO126 are dissolved in dimethyl sulfoxide (DMSO), sole DMSO
treatment served as treatment control (ctrl).
AraC, and UO126 were kindly provided by Prof. M. Dobbelstein, Institute of Molecular
Oncology, University Medical Center Göttingen and Trametinib was a gift from Prof. S.
A. Johnsen, Department of General, Visceral and Pediatric Surgery, University Medical
Center Göttingen and Division of Gastroenterology and Hepatology, Department of
Internal Medicine, Mayo Clinic, Rochester (Minnesota/USA).
Table 1 Sequences of siRNAs. Gene silencing was performed by transfecting
siRNAs by Thermo Scientific using the equivalent volume of siLentFect
lipid reagent (Bio-Rad) in OptiMEM (Gibco, 31 985-62).
Target No Sequence
cJun 155 942 5’-GCG CAU GAG GAA CCG CAU Utt-3’
NFATc1 288 360 5’-GCG UUU CAC GUA CCU UCC Utt-3’
Nfatc1 MSS275 982 5’-AGG ACA GGA AGU AUC CCG AAG GCC C-3’
Smad3 156 946 5’-CGC AGA ACG UGA ACA CCA Att-3’
Smad4 62 739 5’-GGA UUU CCU CAU GUG AUC Utt-3’
For gene silencing experiments, small interfering RNA (siRNA) specific for respec-
tive targets was employed. Sequences used in this thesis are depicted in table 1. In
short, the same volume of the designated siRNA and siLentFect R© lipid reagent (Bio-
Rad) was added to OptiMEM (Gibco, 31 985-62) and incubated for 20 min before
adding the solution to the cells. Overexpression studies were conducted with either a
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SMAD3-FLAG (Feng et al., 1998; Zhang et al., 1998) or SMAD4-HA construct (Ab-
dollah et al., 1997) by transfection with Lipofectamine R© 2000 (invitrogen by Thermo
Fisher Scientific, 11 668 019). As an exception, PaTu8988t cells were always transfected
with TransFastTM (Promega, E2431), due to extreme sensitivity towards Lipofectamine
reagent.
2.1.3 CRISPR/Cas9-mediated Smad4 knock out
Using the double nicking CRISPR/Cas9-mediated genome editing approach, Smad4
WT and k.o. clones of murine NKC-II, KPC Bl6 and human Panc-1 PDAC cells were
established.
To mediate a Smad4-specific gene knock out, sgRNAs (single guide RNAs) for human
and murine Smad4 WT expressing cells were designed, using the tools provided by Ran
et al. (2013b) and Xu et al. (2015). For each species, two sgRNAs were designed to
provide the excision of the complete exon 3 and to introduce a base shift, guaranteeing
Smad4 protein truncation, misfolding and loss of functionality (Ran et al., 2013a).
Subsequently, phosphorylated oligomers were ordered (biomers.net) and cloned into the
px-458 vector bearing the Cas9 endonuclease, a GFP-tag (green fluorescent protein)
and resistance to ampicillin. CRISPR/Cas9 vector was used for E.coli (Escherichia coli)
transformation and plated on LB (lysogeny broth) agarose plates supplemented with
ampicillin. Correct insertion was confirmed by sequencing, and positive E.coli clones
were used to inoculate 100 ml LB medium in order to generate more vector material
for a midi plasmid preparation (Nippon Genetics, FG-90 302). Deoxyribunucleic acid
(DNA) concentration was measured by NanoPhotometer P-Class 360 (intas).
PDAC cells were thawed and subcultivated for one passage. Cells were seeded in 10 cm
dishes and maintained until 60 % confluency before transfection with 5 µg of each con-
struct in addition to 25 µl Lipofectamine R© 2000 (invitrogen by Thermo Fisher Scien-
tific). Successful transfection was confirmed by GFP fluorescence microscopy. After
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Table 2 sgRNAs designed for CRISPR/Cas9-mediated knock out.
sgRNAs were designed using tools provided by Ran et al. (2013b); Xu
et al. (2015). Due to a lack of homology between murine and human
Smad4, different sgRNAs targeting exon 3 were designed for each species.
Knock out strategy involved targeting of introns guiding the respective
exon to enable the complete excision of it.
Number Target Species Sequence
1 Nfatc1 murine 5’-GCTGTAGCTCGGCACTGCAG-3’
2 Nfatc1 murine 5’-TCGTCTCGCAGGCACTGCAG-3’
1 SMAD4 human 5’-TCTAGGTCTGATGTATGACA-3’
2 SMAD4 human 5’-CGACTTTAAATAAGGTTAAA-3’
1 Smad4 murine 5’-TCAGTTAGCTTAGATCTCAG-3’
2 Smad4 murine 5’-CCAGTTCCTGAGGCCTGGC-3’
48 h cultivation, cells were trypsinized and washed twice with PBS. Subsequent to
centrifugation (400 x g, 5 min), cells were resuspended in 1 ml PBS and filtered through
a 50 µm cell strainer (BD Biosciences, 340 631) into a FACS tube (special tube used
for fluorescence-activated cell sorting; Sarstedt, 55.1579) to generate a single cell sus-
pension. Single cell sorting of highly GFP-positive cells was provided by S. Becker,
Department of Hematology and Oncology, University Medical Center Göttingen, using
the FACSAriaII cell sorter (BD Biosciences).
After two weeks, emerging cell colonies were marked and strictly observed. If more than
one colony formed in the same well, this heterogeneous clone was excluded from further
analysis. Upon confluency, cell clones were trypsinized and transferred to a bigger
formats. Cells were taken for genomic DNA (QIAGEN; DNeasy Blood & Tissue Kit,
69 504), RNA and WCL isolation. Cell stocks of all clones were generated and frozen
at −80 ◦C and stored in liquid nitrogen for later use. Promising clones identified by
polymerase chain reaction (PCR) with subsequent band separation on an 1 % agarose
gel [table 12] were sequenced to prove successful Smad4 depletion and no alterations
in potential Smad4 WT clones [see primer sequences in table 3 and general PCR
protocol in 2.5.1]. Upon confirmation of Smad4 status, cells were further characterized
in treatment studies and functional analyses.
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Note that the design of sgRNAs for CRISPR/Cas9-mediated Nfatc1 k.o. in murine
PDAC cells was conducted by myself, while cloning, sorting, expansion of cell clones
and characterization was performed by K. Reutlinger, Department of Gastroenterology
and Gastrointestinal Oncology, University Medical Center Göttingen.
Table 3 Primer sequences for confirmation of Smad4 knock out. Primers
were diluted to 10 µM prior to preparation of reaction mix.
Target Direction Sequence
P1 murine forward 5’-TGC CAC AGT CTT TGC TGT GA-3’
reverse 5’-TTC CCA TAC TGT TTG CAA CAA CC-3’
P2 murine forward 5’-TTC CCT TCA GCA GAA GCT GG-3’
reverse 5’-GCC ATT TCA ATG TAA AAG TGG GGT-3’
P2 human forward 5’-TTT ACA CAT AGT TTC TGC AAC ACA GTC-3’
P1 human reverse 5’-TCT CAA AAA CAA TGT TCT AAA GGG GC-3’
2.2 Functional assays
2.2.1 Annexin V and propidium iodide staining
Cells were seeded in cultivation medium and attached o/n. On the next day, cells
were treated with indicated concentrations of Gemcitabine (Sigma-Aldrich, G6423)
and incubated for 48 h. Then, cells were carefully trypsinized, centrifugated and the
supernatant was aspirated. Subsequently, cells were first washed with Annexin V bind-
ing buffer (Biolegend, 422 201), transferred to a FACS tube and the volume adjusted to
100 µl by decantation. Cells were resuspended in Annexin V binding buffer prior to An-
nexin V (Biolegend, 640920) and propidium iodide (Sigma-Aldrich, P4864) staining for
15 min. Finally, the volume was adjusted to 300 µl before measurement at FACS Canto
II (BD Biosciences) using FACS Diva Software (version 6.1.3). Data were analyzed by
FlowJo software (version 10.1r1) and visualized by GraphPad Prism.
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2.2.2 Migration assay
Cells were seeded in 12 well plates and incubated until confluency. Serum starvation
o/n was followed by introduction of the wound with a 10 µl tip. Subsequently, medium
was removed and cells were washed with PBS prior to adding serum-free medium.
TGFβ was added directly before starting life cell imaging at Leica microscope (DMi8,
CTR advanced), taking one picture per well per hour for 12 h. Migration speed was
evaluated by measuring distance (in µm) of cell borders at three regions per picture
and calculate the mean migration speed of 8 sequential pictures. To evaluate the total
migration distance, cell borders of the start picture were compared to one taken 5 h
later in the same well in a similar approach.
2.2.3 MTT assay
Cell viability and metabolic activity were measured by methylthiazolyldiphenyl tet-
razolium bromide (MTT) assay. 2000 cells per well were plated in quintuplicates in
96 well plates in cultivation medium. Treatment scheme including medium change
and concentration of substances evaluated in this assay are described in the respective
figure legends. On the last treatment day, MTT (Sigma, M5655, 5 mg/ml in aqua
destillata (Aqua dest.)) was added 1:10 into each well, followed by 2 h incubation.
Subsequently, the supernatant was aspirated and cells were disrupted using solubiliza-
tion solution (100 mM HCl and 10 % Triton X-100 in isopropyl alcohol) by shaking for
20 min at RT. Measurements were taken at 595 nm wavelength using a photometer
(Autobio, Phomo). Data were processed by subtracting the background and normal-
izing to treatment control prior to visualization.
For half maximal inhibitory concentration (IC50) evaluation, GraphPad Prism software
was used, utilizing the logarithmic transformation with subsequent nonlinear regression
analysis with sigmoidal shape, defining the end and start values.
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2.2.4 Cell counting assay
Cell counting assay was started by plating 20 000 cells per well in triplicates in a 6
well plate. Every second day, cells were trypsinized and counted prior to replating in a
fresh 6 well plate. Note that the format changed in the last incubation step to a 10 cm
dish to allow unrestricted growth.
2.2.5 Soft agar assay
Soft agar assay was performed in 6 well plates coated with 1 ml 1:1 mix of 1 % noble
agar in Aqua dest. and cultivation medium. Subsequently, a defined number of PDAC
cells in cultivation medium was mixed with 1 % noble agar in Aqua dest. 3:1 and
incubated for 30 min under the bench at RT to ensure solidification prior to adding
2 ml cultivation medium on top. TGFβ was added at this step, utilizing triplicates per
condition. The soft agar assay was incubated for 7 days at 37 ◦C and 5 % CO2 until
final colony counting. Colonies located in 5 different parts per well were counted by
focusing through the solid soft agar.
2.2.6 Sphere assay
For sphere assays, the cell suspension was centrifuged to remove the FBS-containing
medium. Subsequently, cells were resuspended in PBS prior to cell counting. A
defined number of cells was plated in low attachment plates (Thermo Fisher Scien-
tific, Corning Costar cell culture plates, 174 932) using sphere medium (DMEM/F-
12 by Gibco, 11 320-74) supplemented with both epidermal growth factor (EGF) and
fibroblast growth factor (FGF). TGFβ was directly administered to the medium. Both
TGFβ and FGF treatment was repeated every second day until day 7. Final evaluation
was performed by taking 20 random pictures at 200 x magnification per well. Sphere
counting and diameter measurement were performed afterward by using FIJI software
version 1.52j (Schindelin et al., 2012).
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2.3 Molecular methods
2.3.1 Protein isolation
For the preparation of whole cell lysate (WCL), the medium was discarded and cells
were washed once with ice-cold PBS. Subsequently, WCL buffer supplemented with 1 x
cOmpleteTM protease inhibitor cocktail (Roche, 11 697 498 001; Stock: 25 x) was added
in each well [see WCL composition in table 6]. Cells were scraped, lysates collected in
an Eppendorf tube and held on ice for 1 h with repeated vortexing steps. Cell lysates
were centrifugated at maximum speed. The supernatant was transferred into a fresh
Eppendorf tube and stored at −20 ◦C until used.
For nuclear and cytoplasmic lysates, cells were either cultivated in 10 cm or 15 cm
dishes. Upon finalization of the experiment, the medium was discarded and cells were
washed once with ice-cold PBS. 1 ml of PBS was added, cells were scraped and lysates
transferred to Eppendorf tubes. Subsequent to centrifugation at 0.7 x g, 5 min, RT, the
supernatant was aspirated and the cell pellet thoroughly resuspended in a correspond-
ing volume of Buffer A supplemented with 1 x cOmpleteTM (Roche, Stock: 25 x) by
pipette [see composition of Buffer in table 6]. After 20 min incubation on ice, lysates
were centrifugated at 2 x g, 15 min, 4 ◦C. The resulting supernatant contains the cy-
toplasmic fraction and can be transferred to a new Eppendorf tube for storage at
−20 ◦C. The remaining pellet was solved in Buffer C [table 6] supplemented with 1 x
cOmpleteTM protease inhibitor cocktail (Roche, 11 697 498 001; Stock: 25 x). Lysates
were incubated for 1 h on ice with repetitive vortexing steps. Lysates were centrifu-
gated at maximum speed, 20 min, 4 ◦C. The supernatant was transferred into a fresh
tube and lysates were stored at −20 ◦C until used.
Protein concentrations are measured by comparison to bovine serum albumin (BSA)
standard in 1:5 Bradford reagent in Aqua dest. (Bio-Rad, Protein Assay Dye Reagent
concentrate, 5 000 006). Note that BSA standard is solved in the respective protein
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buffer used for the corresponding experiment, namely WCL, A, or C buffer (see buffer
compositions in table 6).
2.3.2 Co-immunoprecipitation
Nuclear lysates were conducted to co-immunoprecipitation studies to investigate nu-
clear complex formation of transcription factors. PBS supplemented with 1 x cOmpleteTM
protease inhibitor cocktail (Roche, 11 697 498 001; Stock: 25 x) was used to add up
150 µg to 200 µg protein lysates to 1 ml. In addition, input samples were generated
from nuclear lysates and stored at −20 ◦C. At the same time, slurry sepharose beads
(Millipore, 16-125, 16-266) were selected according to table 4, washed three times with
PBS and centrifugated at 0.6 x g, 2 min, 4 ◦C. At the final washing step, the super-
natant was aspirated and beads were resuspended in half of the original volume of beads
to create a slurry solution again. For the preclear, 20 µl of slurry beads were added to
each tube and lysates were incubated at the overhead rotator (10 rpm), 4 ◦C for 20 min
to reduce unspecific protein binding. Afterward, tubes were centrifugated at 0.6 x g,
5 min, 4 ◦C and the supernatant carefully transferred to a fresh Eppendorf tube. Anti-
bodies and immunoglobulin G (IgG) controls were added o/n on the overhead rotator
at 10 rpm, 4 ◦C [see table 4].
On the next day, tubes were supplemented with 50 µl PBS-washed slurry sepharose
beads and incubated at the overhead rotator for 2 h. Subsequently, beads were spun
down (0.6 x g, 4 ◦C, 5 min) and the supernatant was aspirated. Beads were washed
five times with 500 µl WCL buffer and three times with 500 µl PBS. Finally, the
supernatant was carefully completely aspirated and beads were incubated with 75 µl
2 x Laemmli buffer (stock: 5 x, diluted in aqua bidest) for 5 min at 95 ◦C before allow
cooling down on ice. This step was repeated once, then samples were spun down and
the supernatant was transferred without any beads to a fresh tube. Samples were
either stored at −20 ◦C or directly used for western blot in combination with the input
samples prepared at the start.
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Table 4 Antibodies for co-immunoprecipitation experiments. Indicated
antibodies were used for co-IP studies in nuclear lysates of human and
murine PDAC cells. Volume of normal rabbit/mouse IgG was adjusted
(adj.) to respective volume of antibody.
Target Company Order number Species Volume [µl] Beads
Flag-tag Sigma F3165-.2MG mouse 3 G
HA-tag abcam ab75640 rabbit 5 A
HA-tag CST 3724 rabbit 5 A
NFATc1 Santa Cruz sc-13033 rabbit 15 A
IgG Santa Cruz sc-2025 mouse adj. G
IgG Millipore 12-370 rabbit adj. A
Smad3 abcam ab28379 rabbit 10 A
2.3.3 Western Blot
Protein samples solved in WCL buffer were adjusted to 1 µg/ml and 5 x Laemmli buffer
supplemented with 5 % β-mercaptoethanol was added. Prepared samples were placed
at 95 ◦C for 5 min with subsequent cooling on ice.
Protein separation according to size was realized using sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE) approaches. For gel preparation, SDS-PAGE,
and blotting, Bio-Rad equipment was used. Gel preparation was conducted accord-
ing to the expected protein sizes, choosing 15 % gels for small sized proteins (< 30
kDa) and 10 % gels for big proteins (30 kDa < x < 180 kDa), respectively [table 5].
20 µg of the respective sample and 4 µl Page Ruler Prestained Protein Ladder (Thermo
Fisher Scientific, 26 617) were loaded before gel run in 1 x Electrophoresis Buffer [see
composition in table 6].
Gels were released from the chamber and conducted to semi-dry turbo blotting us-
ing the Trans-Blot R© TurboTM Transfer System (Bio-Rad; 1 704 150) according to the
manufacturer’s instructions (Bio-Rad; Trans-Blot R© TurboTM RTA Midi Nitrocellulose
Transfer Kit, 1 704 271). Blotting time was adjusted according to desired protein sizes
(fixed: 1.0 A, 25 V). 15 % gels were blotted for 10 min and 10 % gels were blotted for
22 min. The nitrocellulose membrane was stained with Ponceau S solution (Sigma-
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Table 5 Composition of gel solutions. All gel buffers were stored at
4 ◦C. Abbreviations: sodium dodecyl sulfate (SDS), tris(hydroxymethyl)-
aminomethan (Tris), and volume per volume (v/v).
Solution Composition Amount
Stacking Gel Buffer (stock) Tris-base 0.5 M
pH 6.8 SDS 0.4 % (v/v)
Stacking Gel Buffer Stacking Gel Buffer (Stock) 25 ml
Acrylamide 16 ml
Aqua dest. 59 ml
Separating Gel Buffer (stock) Tris-base 1.5 M
pH 8.8 SDS 0.4 % (v/v)
Separating Gel Buffer (10 %) Separating Gel Buffer (Stock) 20 ml
Acrylamide 26.6 ml
Glycerol 4 ml
Aqua dest. 29.3 ml
Separating Gel Buffer (15 %) Separating Gel Buffer (Stock) 20 ml
Acrylamide 40 ml
Glycerol 4 ml
Aqua dest. 16 ml
Aldrich Corporation; P7170) to fix proteins on the membrane and their visualization.
Subsequent to 1 h blocking in Tris-buffered saline (TBS) supplemented with 1 % Tween
and 5 % milk powder at RT, membranes were incubated in primary antibodies using
dilutions described in table 7 o/n at 4 ◦C.
On the following day, antibody dilutions were removed from the membranes and re-
placed by TBS supplemented with 1 % Tween in three washing steps at RT. Af-
terward, horseradish peroxidase-linked (HRP) secondary antibodies (Cell Signaling
Technology (CST); α-rabbit IgG HRP-linked antibody #7074, α-mouse IgG HRP-
linked antibody #7076) were chosen according to the primary antibody’s species and
diluted 1:5000 in TBS supplemented with 1 % Tween and 5 % milk powder at RT
for 1.5 h. Membranes were washed three times with TBS supplemented with 1 %
Tween before protein detection by enhanced chemiluminescence (ECL) method with
ECL Plus (PerkinElmer; NEL105 001EA) or Western Lightning Ultra (PerkinElmer;
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Table 6 Buffers for co-IP and SDS-PAGE. Ingredients were solved
in Aqua dest.. Buffer A, C, and WCL need to be supple-
mented with proteinase inhibitors prior to usage. Abbrevia-
tions: ethylenediaminetetraacetic acid (EDTA), ethylene glycol-
bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and weight per
volume (w/v).
Buffer Composition Concentration








Electrophoresis Buffer Tris-base 250 mM
Glycine 1.92 M
SDS 1 % (w/v)
TBS (pH 7.6) Tris-base 0.2 M
NaCl 1.37 M
WCL HEPES pH 7.5 50 mM
NaCl 150 mM
EGTA 1 mM
Glycerol 10 % (v/v)
Triton X-100 1 % (v/v)
NaF 100 mM
Na4P2O7 x 10 H2O 10 mM
NEL112 001EA) at Intas ECL Chemocam Imager (Intas Science Imaging Instruments).
Protein bands were processed using chemostar software (Intas Science Imaging Instru-
ments) and GIMP software (GIMP (1997), version 2.8.22), while analysis was per-
formed by using FIJI software (Schindelin et al., 2012).
For co-IP blots with targets at 35 to 55 kDa size, membranes were incubated with
α-rabbit light chain specific mouse antibody (CST, #3677) in 1:2000 dilution in TBS
supplemented with 1 % Tween and 5 % milk powder at RT for 1 h prior to incubation
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Table 7 Antibodies for western blot. Antibodies were diluted in 5 % milk
powder in TBS supplemented with 1 % Tween. Membranes were incu-
bated in respective antibody solutions o/n at 4 ◦C .
Target Company Number Species Dilution
β-Actin-HRP Sigma A3854 1:40000
cJun CST 9165 rabbit 1:1000
Erk1/2 CST 9102 rabbit 1:1000
pErk1/2 CST 9101 rabbit 1:1000
Flag-HRP Sigma A8592 1:1000
HA-Tag CST 2367 mouse 1:1000
HA-Tag CST 3724 rabbit 1:1000
Hdac1 CST 2062 rabbit 1:1000
Hdac1 abcam ab33278 rabbit 1:1000
NFATc1 Santa Cruz sc-7294 mouse 1:500
NFATc1 Santa Cruz sc-13033 rabbit 1:500
Parp CST 9542 rabbit 1:1000
Smad2 CST 5339 rabbit 1:1000
Smad2/3 BD Biosciences 610842 mouse 1:500
Smad2/3 CST 3102 rabbit 1:1000
pSmad2/3 CST 8828 rabbit 1:1000
Smad3 CST 9523 rabbit 1:1000
pSmad3 CST 9520 rabbit 1:1000
Smad4 Santa Cruz sc-7966 mouse 1:500
Snai1 CST 3895 mouse 1:1000
with α-mouse HRP-coupled secondary antibody (CST, #7076) in 1:5000 dilution in
TBS supplemented with 1 % Tween and 5 % milk powder at RT for 1.5 h to avoid
heavy chain detection. Note that in this approach it is crucial to perform co-IP using
a rabbit-derived antibody and to choose a rabbit-derived primary antibody on the
membrane.
2.3.4 RNA isolation
Cells were seeded in 6 wells and treated according to the experimental design. Medium
was aspirated and 500 µl TRIzol (ambion, 15 596 018) was added per well. After 5 min
incubation at RT, cells were scraped and transferred into an Eppendorf tube for storage
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at −80 ◦C. For RNA isolation, TRIzol lysates were thawed on ice and 200 µl chloroform
was added. Subsequent to rigorous vortexing, the tubes were incubated for 10 min at
RT. Phase separation was achieved by centrifugation at maximum speed for 15 min
at 4 ◦C. The transparent upper phase was carefully transferred to a fresh tube, 500 µl
isopropyl alcohol was added and the tube was inverted until proper phase mixing.
Tubes were placed in the centrifuge at maximum speed for 30 min at 4 ◦C. The super-
natant was carefully aspirated and replaced by 500 µl 75 % undenatured ethanol. Upon
rigorous vortexing, tubes were centrifuged at maximum speed for 5 min at 4 ◦C. The
supernatant was carefully discarded and tubes were incubated with open lids at RT
until remaining ethanol was evaporated. RNA pellet was resuspended in 30 µl to 50 µl
RNase-free aqua bidest. RNA was stored at −80 ◦C until used.
2.3.5 qRT-PCR
To evaluate and compare gene expression levels, quantitative real time polymerase
chain reaction (qRT-PCR) was performed. Therefore, RNA was transcribed into
complementary deoxyribonucleic acid (cDNA) using iScriptTM cDNA Synthesis Kit
(Bio-Rad; 1 708 890) according to the manufacturer’s suggestions. For the qRT-PCR
approach, cDNA was supplemented with iTaqTM Universal SYBR R© Green Supermix
(Bio-Rad; 172-5121) and specific human or murine messenger ribonucleic acid (mRNA)
primers [see reaction mix in table 8 and primer sequences in table 9]. The experiments
were conducted in three technical replicates using a 96 well plate (Applied Biosys-
tems by Thermo Fisher Scientific, MicroAmp Fast 96-Well Reaction Plate, 4 346 907),
sealed with a film (Applied Biosystems by Thermo Fisher Scientific, MicroAmp Optical
Adhesive Film, 4 311 971) and placed in a StepOne Real-Time PCR system (Applied
Biosystems) running the standard protocol. Data were analyzed using normalization
to the house keeping gene Rplp0 via the ∆∆CT approach.
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Table 8 Reaction mix for qRT-PCR experiments. Reaction mix was pipet-
ted into a 96 well plate (Applied Biosystems), sealed and placed in a
StepOne system (Applied Biosystems).
Ingredients 1 x
Sybr Green 5 µl
Primer forward 0.05 µl
Primer reverse 0.05 µl
Aqua bidest 3.9 µl
cDNA 1 µl
Table 9 Primer sequences for qRT-PCR experiments. Primers were di-
luted to 10 µM in Aqua dest. prior to preparation of reaction mix [see
table 8].
Target Direction Sequence
Cda forward 5’-TCA GCC TAC TGC CCC TAC AG-3’
reverse 5’-AGC AGG CGT TTT CTA TGT TGC-3’
Cdc20 forward 5’-CTG TCT GAG TGC TGT GGA TG-3’
reverse 5’-AAA GCC GTG ACC TGA GAT C-3’
Cks1b forward 5’-CAC TGC CCA AGA AGC CAA AG-3’
reverse 5’-ACA TGG TCA CGC GAT CAG AA-3’
Dctd forward 5’-CAA ACC TCA CTG GGA ACC GTA-3’
reverse 5’-GGG AGC CAG AGC TTA TCC C-3’
Fgfbp1 forward 5’-ACT CAC AGA AAG GCA CTT GGA-3’
reverse 5’-CTG AGA ACG CCT GAG TAG CC-3’
Mcm4 forward 5’-GTG AGG AAA GCA GGT CGT CA-3’
reverse 5’-ACA AGG CAT TCT GTG CAG GT-3’
Nfatc1 forward 5’-GCC TTT TGC GAG CAG TAT CT-3’
reverse 5’-GCT GCC TTC CGT CTC ATA GT-3’
Rrm1 forward 5’-ATC TTA CTG AGC GGG GCT TG-3’
reverse 5’-ATG AAA GCA CCT CTC TCG GC-3’
Rrm2 forward 5’-TTT GCC GCC GTA GAA GGA AT-3’
reverse 5’-ATC AGC CCC CGT TTC TTG AG-3’
Rplp0 forward 5’-TGG GCA AGA ACA CCA TGA TG-3’
reverse 5’-AGT TTC TCC AGA GCT GGG TTG T-3’
Smad4 forward 5’-GTG ATC TAT GCC CGT CTG TG-3’
reverse 5’-ATT ACT CTG CAG TGT TAA TC-3’
Smad7 forward 5’-TGC TCC CAT CCT GTG TGT TAA G-3’
reverse 5’-TCA GCC TAG GAT GGT ACC TTG G-3’
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2.4 RNA sequencing and bioinformatic analyses
Prior to library preparation for RNA sequencing (RNAseq), RNA integrity and purity
was evaluated by separation and visualization on an 1 % agarose gel supplemented with
Midori Green Advance (Biozym, 617 004).
Library preparation was performed using Illumina kits (RS-122-2001; RS-122-2002)
according to the manufacturer’s instructions. Qubit measurement (Thermo Scientific,
Q32 854) controlled cDNA concentrations and fragment sizes were measured by Agilent
2100 bioanalyzer high sensitivity DNA analysis kit (Agilent, 5067-4626) utilizing Agi-
lent 2100 Expert software. Subsequent to preparation of 5 nM mastermix, the sample
was given for sequencing to Transcriptome and Genome Analysis Laboratory of the
University Medical Center Göttingen, Germany.
RNAseq data were uploaded to the public server at usegalaxy.org (Afgan et al., 2018).
TopHat tool (Kim et al., 2013) (version 2.1.1) with very sensitive bowtie2 settings
and subsequent sorting by SortSam (version 2.18.2.1) was used to map Fastq files
to the murine transcriptome (mm9). After read counting via HTSeq (Anders et al.,
2015) (union mode; version 0.9.1), DESeq2 (Anders & Huber, 2010; Love et al., 2014)
was employed to measure principal component analysis (PCA) and sample-to-sample
distances for assessing similarities between replicates. Cuffdiff (version 2.2.1.5) and
Cuffnorm tools (geometric; version 2.2.1.2) conveyed differential regulation analysis
and normalized fragment counts, respectively (Trapnell et al., 2012; Ghosh & Chan,
2016). For further analysis, fragments per kilobase million (FPKM) threshold > 5 was
established to reduce background. Heatmaps are based on z scores of each replicate.
These data were processed using hierarchical clustering by Cluster 3.0 (Euclidean dis-
tance; version 1.54) in combination with Java TreeView (version 1.1.6r4) (Saldanha,
2004).
Potential NFATc1/Smad3/cJun targets were conducted to gene ontology (GO) analy-
sis (Ashburner et al., 2000; The Gene Ontology Consortium, 2017) to determine their
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functional relevance. The overrepresentation test of protein analysis through evolu-
tionary relationships (PANTHER; version 14.0) was employed with Fisher’s exact test
using either Bonferroni correction for multiple testing (p value) or the false discovery
rate (FDR) to assess the functional relevance by classification with the GO biological
process complete algorithms (Thomas et al., 2003; Mi et al., 2013).
Datasets for genes associated in unfavorable or favorable prognosis in PDAC were
extracted from the human protein atlas (Cancer Genome Atlas Research Network et al.,
2013; Uhlen et al., 2017) and processed by gene set enrichment analysis (GSEA). GSEA
(Mootha et al., 2003; Subramanian et al., 2005) was conducted with Signal2Noise metric
and FDR < 0.25 was considered significant. Normalized enrichment score (NES) served
as the primary statistic.
To compare murine Smad4-dependent survival data to human PDAC patients, The
Cancer Genome Atlas (TCGA) data (Cancer Genome Atlas Research Network, 2017)
were analyzed with OncoLnc tool (Anaya, 2016) by setting percentiles at 25 (patient
groups n = 43, respectively).
2.5 Genetically engineered mouse models
Functional assays and pathway analysis performed in cell culture were expanded by in
vivo studies employing GEMMs of Smad4 deficiency.
2.5.1 GEMM breeding
Investigating implications of Smad4 deficiency in vivo was executed by both employing
mice harboring flox/+ (heterozygous) (fl/+) or flox/flox (homozygous) (fl/fl) depletion
of Smad4. Smad4 fl/fl mice as described by Yang et al. (2002) were ordered by Charles
River Laboratories, Germany. Interbreeding with mice bearing p48-Cre recombinase
(Hingorani et al., 2003) resulted in conditional deletion of Smad4 exon 8 in the pan-
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creas, leading to protein misfolding and premature degradation. In our animal breeding
system, both homozygous and heterozygous Smad4 depletion was introduced to mice
bearing conditional KrasG12D activation controlled by p48-Cre (Yang et al., 2002; Hin-
gorani et al., 2003). This resulted in Smad4fl/+; KrasG12D; p48-Cre (SKC fl/+ p48)
and Smad4fl/fl; KrasG12D; p48-Cre (SKC fl/fl p48) mice that were analyzed in survival
studies or sacrificed at defined time points (4 weeks, 8 weeks, 12 weeks, and 6 months,
respectively). Kras WT littermates were employed in the same studies as controls. The
following end-point criteria were employed for survival studies: development of ascites,
body weight loss (> 20 %), lethargy or lack of social behavior. Importantly, KrasG12D;
p48-Cre (KC p48) control animals were bred and sacrificed as part of the medical
doctorate thesis of B. Steuber, Department of Gastroenterology and Gastrointestinal
Oncology, University Medical Center Göttingen.
Mouse genotyping was performed by DNA isolation from tail or ear biopsies. Respective
biopsies were incubated in Alkaline Lysis Buffer (25 mM NaOH, 0.2 mM EDTA) at
95 ◦C for 30 min before adding the same volume of Neutralization Buffer (40 mM Tris-
HCl). Samples were stored at −20 ◦C.
Table 10 Primer sequences for genotyping. Primers were diluted to 10 µM
prior to addition to PCR reaction mix.
Target Direction Sequence
Smad4 forward 5’-TAA GAG CCA CAG GGT CAA GC-3’
reverse 5’-TTC CAG GAA AAA CAG GGC TA-3’
Kras forward 5’-AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC G-3’
reverse 5’-CCT TTA CAA GCG CAC GCA GAC TGT AGA-3’
p48-Cre forward 5’-TGC TGT TTC ACT GGT TAT GCG G-3’
reverse 5’-TTG CCC CTG TTT CAC TAT CCA G-3’
Mouse strains were genotyped by PCR with subsequent band separation by PerfectBlue
Horizontal Maxi Gel Systems (Peqlab, 700-540) and visualization by agarose gel at
ultraviolet transilluminator (Bio-Rad, ChemiDoc XRS+). PCR mix (Nippon Genetics,
KK5621, KAPA2G Fast Hot Start Genotyping Mix with Dye) was supplemented with
DNA derived from mice tail biopsies and genotyping primers depicted in table 10
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Table 11 Reaction mix for genotyping PCR. PCR was performed in T100




Primer forward 0.5 µl
Primer reverse 0.5 µl
Aqua bidest 4.25 µl
Genomic DNA 1 µl
Table 12 PCR protocols. The following PCR programs were realized on T100
Thermal Cycler (Bio-Rad) and the product was subsequently separated
by agarose gel. (a) shows the protocol for the validation of potential
CRISPR/Cas9 k.o. and WT clones, while (b+c) refer to genotyping
PCRs validating the respective GEMMs.
(a) CRISPR/Cas9 validation
Temperature Time
95 ◦C 3 min
35 x
95 ◦C 30 sec
63 ◦C 30 sec
72 ◦C 30 sec
72 ◦C 1 min
(b) Kras and p48-Cre
Temperature Time
95 ◦C 2 min
35 x
95 ◦C 30 sec
60 ◦C 30 sec
72 ◦C 60 sec
72 ◦C 5 min
(c) Smad4
Temperature Time
94 ◦C 2 min
10 x 94 ◦C 20 sec
−1.5 ◦C/cycle 65 ◦C 15 sec
68 ◦C 10 sec
28 x
94 ◦C 15 sec
50 ◦C 15 sec
72 ◦C 10 sec
72 ◦C 2 min
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[reaction mix in table 11]. Subsequent to PCR in T100 Thermal Cycler (Bio-Rad,
186-1096) [see PCR protocol in table 12], samples were loaded on respective agarose
gels supplemented with Midori Green Advance. Note that Smad4 primers produce a
double band on a 2 % agarose gel in heterozygous k.o. as Smad4 WT PCR product’s
length is 436 base pair (bp) and mutated Smad4 500 bp.
All procedures were carried out using protocols approved by the Institutional Animal
Care and Use Committee at the University Medical Center Göttingen and respective
mice are listed under the animal approval number 33.9-42502-04-14/1634.
2.5.2 Tissue processing
Mice were sacrificed using CO2 prior to cervical dislocation and heart disruption. Sub-
sequent to opening the abdomen, pancreatic tissue was isolated and divided into 4
parts from head to tail. While part 1 and 3 were immediately snap frozen in liquid
nitrogen for later RNA or protein isolation, the remaining tissue was incubated in 4 %
paraformaldehyde in PBS for 24 h at RT for tissue fixation. Additionally, parts of liver
and spleen were added for fixation. The next day, tissue in paraformaldehyde solu-
tion underwent a dehydration series performed by Leica Tissue Processor (TP1020).
The last steps included incubation in paraffin and tissue block preparation using Le-
ica embedding system (EG1150H). Tissue blocks were allowed to solidify at HistoCore
Arcadia C cooling plate (Leica, 14 600 005 015) prior to storage at RT in the dark.
Sectioning by microtome (Leica, RM2265) was performed by applying 4 µm sections
on slides with subsequent incubation at 37 ◦C o/n prior to storage at RT in the dark.
2.5.3 HE and IHC
For hematoxylin and eosin (HE) and IHC staining, tissue sections passed through a
rehydration series starting with Roticlear (Carl Roth, A538) transferring to Ethanol
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dilutions, ending in tap water. For HE stainings, slides were then dyed in hematoxylin
solution according to Mayer (Sigma, 51 275) with subsequent incubation under running
tap water. Next, sections were counterstained with eosin y solution (Sigma-Aldrich,
HT110 232) prior to dehydration series ending in Roticlear. Cover slips were mounted
using mounting medium (Carl Roth, HP68.2).
Table 13 Composition of antigen retrieval buffers. Buffers were filled up to
1 l with Aqua bidest.
Solution Components Amount
Citrate Buffer Citric acid monohydrate 2.1 g
pH 6
TE Buffer (10 x) Tris-Base 12.1 g
pH 9 EDTA 3.7 g
Table 14 Composition of washing buffer. Buffer was filled up to 5 l with Aqua
bidest.
Solution Components Amount
PB washing buffer NaH2PO4 x H2O 12.05 g
pH 7.4 Na2HPO4 x 2 H2O 56.7 g
PBS washing buffer KCl 1 g
pH 7.2 to 7.4 KH2PO4 1 g
Na2HPO4 x 2 H2O 3.8 g
NaCl 40 g
IHC stainings required heat-induced epitope retrieval using either citrate or Tris EDTA
(TE) buffer indicated in table 13. Subsequently, slides were allowed to cool down in
their respective antigen retrieval buffers in an ice box. Signal of endogenous peroxi-
dase was reduced by incubation in 3 % hydrogen peroxide solution. Slides were aligned
into SequenzaTM Slide Rack and washed with PBS supplemented with 1 % Tween-20
or Triton X-100 depending on the primary antibody (table 14). Unspecific binding
was reduced by incubation with 10 % BSA in the respective washing buffer prior to
adding the primary antibody diluted in the same solution. For PDAC staining, we
employed NFATc1 (abcam, ab2796; citrate buffer; 1:100 in PBS-Triton X-100), Smad3
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(abcam, ab28379; TE buffer; 1:500 in PBS-Tween-20) and Smad4 antibody (Santa
Cruz, sc-7966; citrate buffer; 1:200 in PBS-Tween-20), respectively. Murine slides
were stained for Smad4 using an alternative antibody (CST, 46 535; citrate buffer;
1:200 in PBS-Triton X-100). Primary antibody was incubated o/n at 4 ◦C. The next
day, slides were washed with their respective washing buffer prior to secondary anti-
body prior to Streptavidin-Biotin complex incubation according to the manufacturer’s
protocol (Biozol, Vectastain ABC Kit, PK-4001 and PK-4002). Subsequently, 3,3’-
diaminobenzidine (DAB) staining (Vector, DAB ImmPACT, SK-4105) was precisely
timed and counterstained by hematoxylin before dehydration series and mounting.
2.5.4 IF and PLA
For immunofluorescence (IF) and proximity ligation assay (PLA) experiments, murine
PDAC slides were rehydrated as described in 2.5.3. Heat-activated antigen retrieval was
performed using citrate buffer. Tissue was encircled by Dako Pen (Agilent, S200 230-
2) and washed with phosphate buffer (PB) + 0.4 % Triton X-100 prior to 1 h blocking
with 10 % normal goat serum in PB + 0.4 % Triton X-100 at RT. NFATc1 (abcam,
ab2796; 1:100) and Smad3 (CST, 9523; 1:100) primary antibodies were incubated o/n
at 4 ◦C.
For IF stainings, secondary antibodies (abcam, ab175 473 and ab; 1:1000) were incu-
bated for 2 h at RT prior to 4’,6-diamidino-2-phenylindole (DAPI) staining (Sigma-
Aldrich, D9542; 1:2000) and cover slip mounting (Thermo Scientific, 9 990 402).
The second day of PLA experiments was conducted using the Duolink R© in situ Kit ac-
cording to the manufacturer’s protocol (Sigma, DUO92 101). Mounting was performed
using DAPI-supplemented mounting medium (Vector, Vectashield, H-1200). IF and





In this work we investigated the interplay of the inflammatory transcription factor
NFATc1 with active TGFβ signaling in PDAC. To scrutinize if and under which
specific conditions NFATc1 and SMAD3 directly interact, we developed several model
systems covering different genetic aspects distinctive for PDAC heterogeneity. In the
first part, we scrutinized how loss of SMAD4 drives PDAC development by altering
the functional characteristics of the cell. In this context, we elucidated conditions
favorable for nuclear NFATc1/SMAD3 complex assembly by employing PLA and co-IP
approaches. The second part provided insights into chemotherapeutic resistance and
sensitivities as a consequence of SMAD4 deficiency and highlighted the crucial role of
AP-1 proteins for nuclear NFATc1/SMAD3 complex formation. Pathways regulated by
NFATc1/SMAD3 transcription complexes were examined via genome-wide expression
studies.
3.1 Nuclear NFATc1/Smad3 complexes in
Smad4-deficient PDAC
To understand the implications of Smad4 depletion in the context of oncogenic Kras
activation in the pancreas, we first explored murine in vivo models to assess loss of
Smad4 as a tumorigenic driver in the context of NFATc1 WT expression. Secondly,
we employed CRISPR/Cas9-mediated genome editing to investigate complete loss of
Smad4 in epithelial tumor cell lines in vitro. Both approaches aimed to scrutinize the
conditions shaping the interplay of NFATc1 and Smad3 transcription factors in PDAC.
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3.1.1 A murine model of Smad4 deficiency recapitulates features
of human PDAC
First of all, we employed human PDAC data gathered by TCGA (Cancer Genome
Atlas Research Network, 2017; Anaya, 2016) to check for SMAD4-dependent patient
survival. Comparing SMAD4 low and high expressing PDAC-derived patient sam-
ples, we confirmed Smad4 deficiency being associated with dismal prognosis [Figure 4
A], thus suggesting SMAD4 deficiency as a prognostic marker for accelerated PDAC
progression and decreased outcome (394 d versus 476 d, respectively).
Investigating Smad4-dependent tumorigenesis in PDAC included the generation of a
GEMM that either maintained Smad4 WT status (KC p48), harbored a heterozygous
Smad4 k.o. (SKC fl/+ p48) or homozygous Smad4 k.o. (SKC fl/fl p48). Importantly,
we controlled how and to which extend homozygous and heterozygous Smad4 depletion
could be visualized via IHC [Figure 5]. KC p48 mice demonstrated Smad4 positive
nuclei of PanIN lesions, while in SKC fl/fl p48 mice Smad4 positive stromal cells served
as staining control. However, partial Smad4 depletion in SKC fl/+ p48 mice did not
result in abrogation of Smad4 protein expression in the nuclei of PanINs.
The KC p48 mouse first introduced by Hingorani et al. (2003) is an established model
for slowly progressing PDAC with a median survival of 493 d [Figure 4 B]. In contrast,
upon introduction of conditional Smad4 k.o. animals by Yang et al. (2002), there have
been only a few murine Smad4 deficiency studies in the pancreas (Izeradjene et al.,
2007; Kojima et al., 2007; Whittle et al., 2015) covering different Cre recombinases
and p53 conditions. Our mouse model faithfully recapitulated Smad4-dependent sur-
vival as already observed in human PDAC patients, with reduced Smad4 expression
being associated with decreased GEMM lifespan (SKC fl/fl p48: 129 d). In contrast
to Izeradjene et al. (2007), we already noticed significant reduction of median sur-






Figure 4 PDAC-associated survival is decreased upon Smad4 deficiency.
A TCGA-derived patient data were analyzed according to SMAD4 sta-
tus, considering the lower and upper percentiles (25:25) of SMAD4 sig-
nal. Patients associated with weak SMAD4 expression reveal a median
survival of 394 d in contrast to 476 d in SMAD4 high expressing patients
(n = 43, respectively). B Animal survival studies were conducted with
Smad4 WT, heterozygous Smad4 k.o. or homozygous Smad4 k.o. bear-
ing GEMM of pancreatic cancer. The PDAC-associated median survival
of 20 individuals per group is 493 d in KC p48, 307.5 d in SKC fl/+ p48
and 129 d in SKC fl/fl p48, respectively.
In addition to survival studies in aforementioned GEMMs, mice were sacrificed at 4
weeks, 8 weeks, 12 weeks and 6 months of age to investigate the formation of preneo-
plastic lesions and PDAC in detail. HE stainings illustrate gradual preneoplastic lesion
development between 4 weeks and 12 weeks of age [Figure 6]. Already 4 weeks after
birth, homozygous and heterozygous loss of Smad4 accelerates the formation of ADM
and PanINs compared to KC p48 mice. Accordingly, the comparison of pancreas weight
normalized to the corresponding body weight revealed significant differences inbetween
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Figure 5 Homozygous Smad4 depletion abrogates epithelial Smad4 pro-
tein expression in the pancreas. Smad4 IHC demonstrated no re-
duction in staining of PanIN nuclei upon heterozygous Smad4 deficiency
but complete loss in acini and preneoplastic lesions of SKC fl/fl p48
mice, while its expression was maintained in stromal cells.
genotypes from the age of 4 weeks onwards [Figure 7]. In each of the defined time
points, the relative pancreas weight of SKC fl/fl p48 mice was significantly increased
compared to the Smad4 WT or heterozygous k.o. models, indicating tremendous ac-
celeration of preneoplastic lesion formation upon homozygous Smad4 depletion in the
context of oncogenic Kras activation. Importantly, PDAC formation occurred in the
context of homozygous Smad4 depletion already at 8 weeks of age, with extensive
desmoplasia leading to drastic gain of relative pancreas weight [Figure 7]. Pancreata
of SKC fl/+ p48 mice significantly differed from KC p48 animals, demonstrating that
partial loss of Smad4 was sufficient in driving PanIN and ADM formation beyond
Smad4 WT controls. For SKC fl/fl p48 mice, first metastases in the liver were de-
tectable at 12 weeks of age which is in line with 100 % tumor incidence in 12 weeks
old SKC fl/fl p48 animals [Figure 8, see number of included animals in Figure 7]. In
contrast, age-matched KC p48 and SKC fl/+ p48 mice did not progress to PDAC at
12 weeks of age and show healthy liver tissue. For the majority of SKC fl/+ p48 mice,
tumor formation occurred between 12 weeks and 6 months of age, which is significantly
earlier as in KC p48 mice. The acceleration of PDAC formation upon complete loss
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Figure 6 Smad4 deficiency accelerates formation of preneoplastic lesions
and PDAC. HE stainings of 4 weeks, 8 weeks, and 12 weeks old mouse
pancreata of the indicated genotypes reveal accelerated PanIN formation
and progression upon loss of Smad4. Liver sections of 12 week old
GEMM demonstrate early metastasis formation in SKC fl/fl p48 mice
[asterisk].
of Smad4 is in agreement with the observed significant differences in tumor-associated
survival [Figure 4]. Importantly, only one SKC fl/fl p48 mice survived until 6 months
of age, while others died prematurely due to severe tumor burden. SKC fl/+ p48 mice
developed PDAC earlier than corresponding KC p48 animals, proposing the idea that
already partial loss of Smad4 accelerated PDAC aggressiveness. This is in agreement
with premature tumor-associated death of SKC fl/+ p48 animals compared to Smad4
WT bearing KC p48 mice. Kras WT expressing littermates of KC p48, SKC fl/+ p48,
and SKC fl/fl p48 did not show any significant differences in relative pancreas weight in
the aforementioned defined time points [data not shown]. The combination of survival
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4 weeks old GEMM 8 weeks old GEMM
12 weeks old GEMM 6 months old GEMM
n = 7        n = 12       n = 12 n = 11   n = 10       n = 11
n = 14        n = 12       n = 13 n = 9 n = 14         n = 1
Figure 7 Smad4 deficiency accelerates gain of relative pancreas weight.
Relative pancreas weight of indicated GEMMs is assessed by normalizing
the pancreas weight to corresponding mouse body weight. Number of
analyzed individuals is indicated for each defined time point.
Figure 8 Smad4 deficiency hastens PDAC formation. PDAC development
of indicated GEMMs was evaluated by analysing HE stainings of re-
spective pancreata at the age of 4, 8, and 12 weeks and 6 months,
respectively.
studies, analysis of relative pancreas weight, morphological assessment and evaluation
of tumor incidence demonstrates that homozygous loss of Smad4 severely accelerates
PDAC formation and PDAC-associated mortality in Kras-driven GEMMs. Moreover,
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partial Smad4-depletion also hastens tumorigenesis and accelerates PDAC-associated
mortality beyond the KC p48 model, but not to the extent observed for SKC fl/fl p48
mice.
KC p48 SKC fl/+ p48 SKC fl/fl p48A
B C
n = 34 n = 32n = 21
D
KC p48 SKC fl/+ p48 SKC fl/fl p48














Figure 9 Homozygous loss of Smad4 favors metastasis formation in low
grade PDAC. A Tumor stage was assed via evaluation of HE staining
by Prof. P. Ströbel, Institute of Pathology, University Medical Center
Göttingen. B Abundance of hepatic metastasis formation was evalu-
ated using HE stainings in tumor-bearing animals of indicated geno-
types. C Masson’s trichrome staining for the evaluation of collagen de-
position in tumor-bearing KC p48 (n = 3), SKC fl/+ p48 (n = 7) and
SKC fl/fl p48 mice (n = 7) was performed by Dr. med. H. Bohnen-
berger. Per animal, 10 pictures were taken at 200 x and the positive
fraction was normalized to total PDAC area in the corresponding pic-
ture. D Representative pictures of Masson’s trichrome staining in the
respective GEMM illustrate differences in PDAC architecture.
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In the next step, we aimed to figure out whether the extreme aggressiveness of Smad4-
depleted PDAC was reflected in the corresponding tumor stages. PDAC grading of
tumor-bearing KC p48, SKC fl/+ p48 and SKC fl/fl p48 mice was performed by Prof.
P. Ströbel, Institute of Pathology, University Medical Center Göttingen [Figure 9 A].
Surprisingly, all SKC fl/fl p48-derived tumors met the criteria of low-grade G1 PDAC.
In contrast, heterozygous Smad4 depletion favored the development of G2 tumors with
reduced incidence of both G1 and G3 staged tumors. The established KC p48 model
formed comparably more G1 and G3 tumors, thus representing the model system with
the highest abundance of poorly differentiated PDAC. Accordingly, we checked for
metastasis formation in HE-stained liver sections of all tumor-bearing GEMMs [Figure
9 B]. In agreement with the observed gain of PDAC aggressiveness upon homozygous
Smad4 depletion, the metastatic burden was increased in the SKC fl/fl p48 model
compared to the others. This is of particular interest as the life span of SKC fl/fl p48
mice was up to 2 to 3 times shorter than KC p48 and SKC fl/+ p48 mice employed
in this analysis. These contradictory data imply that not the tumor differentiation as
evaluated by tumor grading but rather the PDAC architecture is the crucial factor in
metastatic spread. To investigate differences in tumor composition, we analyzed col-
lagen abundance as visualized by Masson’s trichrome staining performed by Dr. med.
H. Bohnenberger, Institute of Pathology, University Medical Center Göttingen [Figure
9 C,D]. Here we identified significantly increased collagen deposition upon homozy-
gous Smad4 depletion as compared to heterozygous loss of Smad4 and Smad4 WT
in the context of oncogenic Kras activation. Although SKC fl/+ p48 mice developed
comparably higher PDAC stages corresponding to rather dedifferentiated tumors, the
metastasis formation remained at the same level as in KC p48 mice, demonstrating
that partial Smad4 depletion was insufficient in driving processes leading to different
tumor structure and promoting metastasis.
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3.1.2 NFATc1 and Smad3 cooperate in Smad4 deficiency
Apart from phenotypic analyses of GEMMs bearing Smad4 WT, heterozygous Smad4
k.o. or homozygous Smad4 depletion in the context of oncogenic Kras activation, we
aimed to focus on Nfatc1/Smad3 cooperativity in the aforementioned models. IF stain-
ing in SKC fl/fl p48-derived PDAC tissue revealed colocalization of respective Nfatc1
and Smad3 signals [Figure 10]. Smad3 was detected preferably in acini, PanIN lesions,
tumor cells and immune cells. Strong Nfatc1 signal, however, was spotted in immune
cells and potential invading cancer cells, respectively. Embedded in tumor stroma,
NFATc1 and Smad3 double positive cells were identified [see arrowheads in Figure 10].
However, simultaneous Nfatc1 and Smad3 expression is a prerequisite for the existence
of Nfatc1/Smad3 complexes which needed to be validated in further experiments.
Nfatc1 Smad3 DAPI MERGED
SKC fl/fl p48
Figure 10 Nfatc1/Smad3 double positive tumor cells in Smad4 defi-
ciency. Pancreatic tissue containing healthy acinar cells, PanIN le-
sions and differentiated PDAC was stained for Nfatc1 (red) and Smad3
(green) via IF. Arrowheads mark double positive cells surrounded by
tumor stroma. Blue DAPI staining highlights nuclei. Magnification is
set at 400 x.
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Figure 11 Nfatc1/Smad3 complexes in PDAC and immune cells. PDAC
tissue of KC p48, SKC fl/+ p48, SKC fl/fl p48, and KPC Bl6 ortho-
topically transplanted tumor cells were utilized for an in situ PLA
assay. Yellow signal indicates Nfatc1/Smad3 complexes while nuclei
are counterstained with DAPI.
To investigate Smad4-dependent Nfatc1/Smad3 complex formation using the endoge-
nous expression levels, we performed in situ fluorescence-based PLA studies on PDAC
tissue derived from KC p48, SKC fl/+ p48 and SKC fl/fl p48 mice, respectively [Fig-
ure 11]. As a negative control, we processed PDAC tissue from KPC Bl6 Nfatc1 k.o.
orthotopically transplanted tumor cells which was provided by D. Spyropoulou, De-
partment of Gastroenterology and Gastrointestinal Oncology, University Medical Cen-
ter Göttingen as part of her medical doctoral thesis. Based on close proximity of
Nfatc1 and Smad3, rolling circle DNA synthesis of oligonucleotide-bearing secondary
antibodies is exploited to visualize Nfatc1/Smad3 complexes via fluorescence-labeled
DNA probes. Nuclear staining by DAPI was used to evaluate the cellular location of
observed Nfatc1/Smad3 complexes. In the KC p48 and SKC fl/+ p48 model, there
was occasional detection of Nfatc1/Smad3 complexes in cells with small circular nuclei
detached from epithelial structures, hinting towards nuclear Nfatc1/Smad3 complexes
in immune cells. The most frequent occurrence of Nfatc1/Smad3 signal was identified
in SKC fl/fl p48 PDAC. As observed for the IF staining in the same tumor, we pro-
pose nuclear Nfatc1/Smad3 complex formation in invading tumor cells and immune
cells, respectively, while there was no detection in preneoplastic lesions. In agree-
ment with KC p48 and SKC fl/+ p48-derived tissue, Nfatc1/Smad3 complexes were
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detected in the periphery of epithelial structures and within comparably more ded-
ifferentiated PDAC. In our KPC Bl6 Nfatc1 k.o. control, we recognized weak signal
of Nfatc1/Smad3-bearing host-derived immune cells in the anaplastic tumor, thereby
























Figure 12 NFATc1 cooperates with SMAD3 in SMAD4-deficient hu-
man PDAC. A Exemplary IHC stainings of NFATc1, SMAD4,
and SMAD3 in human PDAC tissue. B Stratification according to
NFATc1, SMAD4, and SMAD3 expression and localization in the tu-
mor cell as assessed by IHC in human TMA.
Finally, we aimed to confirm the prevalence of nuclear NFATc1 signal combined with
robust nuclear SMAD3 expression in patient-derived PDAC tissue in the context of
SMAD4 deficiency. Wilentz et al. (2000b) and Liszka (2014) described IHC as a reliable
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tool to assess the SMAD4 status of cells. Both loss of heterozygosity (LOH) subsequent
to truncation or depletion of one allele leads to a complete loss of staining. Meanwhile,
unaltered immune cells and fibroblasts serve as SMAD4 staining controls. Nuclear
localization of NFATc1 and SMAD3 was interpreted as a measure for transcriptional
activity [Figure 12 A]. Of all analyzed patient-derived PDAC samples (n = 75), two
thirds stained positive for nuclear NFATc1 [Figure 12 B]. This patient cohort was
further analyzed according to SMAD4 status, revealing 40.8 % of SMAD4-depleted
patient tissues. Regardless of SMAD4 status, in this patient collective, SMAD3 was
preferably situated in the nucleus, with a tendency of increased SMAD3 activation in
the context of SMAD4 deficiency. The tissue microarray (TMA) analysis of human
PDAC confirmed the existence of a patient subgroup with strong nuclear accumulation
of NFATc1 and SMAD3 in the context of SMAD4 depletion (36.7 %).
Via IF and in situ PLA approaches, we confirmed the existence of nuclear Nfatc1/Smad3
cooperativity and complex formation predominantly in the context of homozygous
Smad4 depletion. However, if and to what extend Nfatc1/Smad3 complex-driven
transcription is contributing to the extreme acceleration of PDAC progression in the
SKC fl/fl p48 model remains a matter of investigation. Phenotypic analyses suggest
that heterozygous loss of Smad4 is already a sufficient promoter of preneoplastic lesion
formation and PDAC establishment leading to reduced survival of SKC fl/+ p48 mice
compared to KC p48. Detailed molecular analyses in all three GEMMs are limited by
weak endogenous Nfatc1 protein expression, suggesting the introduction of additional
experimental systems to elucidate if and under which circumstances the inflammatory
transcription factor Nfatc1 interacts with Smad3 for joint regulation of gene expression.
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3.1.3 Smad4 deficiency favors nuclear NFATc1/Smad3 complex
assembly
For an in-depth analysis of conditions driving or disrupting nuclear NFATc1/Smad3
transcription complex assembly, we switched to another model bearing NFATc1 over-
expression. Therefore, we relied on primary murine PDAC cells derived from NKC p48
mouse model introduced by Baumgart et al. (2014). Those NKC-II cells are character-
ized by constitutive nuclear HA-tagged NFATc1 along with oncogenic Kras activation
causing a dramatic acceleration of tumorigenesis and thus mimicking the aggressive
nature of human PDAC (Baumgart et al., 2014). Importantly, those NKC p48-derived
primary PDAC cells maintained Smad4 WT status and remained responsive to TGFβ
treatment (Hasselluhn et al., in revision).
Given that IF and PLA experiments in GEMMs with different Smad4 states suggested
Nfatc1/Smad3 complex formation preferably in the context of Smad4-depleted PDAC,
we further aimed at investigating NFATc1/Smad3 complex formation in a Smad4-
dependent manner. Hence, we applied CRISPR/Cas9-mediated genome editing by
transfecting two corresponding sgRNA sequences targeting exon 3 of the Smad4 gene.
Subsequent GFP-guided single clones sorting by FACS and clonal growth led to the
establishment of NKC-II Smad4 k.o. cell line. As a control, we picked another clone
which underwent the same procedure and selection pressure but maintained its Smad4
WT status as confirmed by sequencing [data not shown]. Based on genomic DNA
extracted from parental cells and CRISPR/Cas9 clones, targeted PCR for the Smad4
locus was performed. The PCR product was separated on an agarose gel to visualize the
loss of 550 bp in the Smad4 gene [Figure 13 A]. Loss of exon 3 introduces a frameshift
into the nucleotide sequence, leading to truncation and misfolding of the Smad4 protein.
Accordingly, we checked for Smad4 protein expression via western blot and further
verified the integrity of TGFβ signaling in Smad4 WT and -deficient clones [Figure 13
B]. Importantly, we aimed to preserve unaltered TGFβ response in the CRISPR/Cas9
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NKC-II: murine; KrasG12D; NFATc1-HA c.n.
Smad4 WT Smad4 k.o.
NKC-II
Figure 13 Establishment of CRISPR/Cas9-mediated Smad4 knock out
in NKC-II cells. A Genomic DNA of parental NKC-II cells and
two CRISPR/Cas9 clones PCR of Smad4 locus using primer pair P1
separated by an agarosel gel. B Western blot analysis of indicated
proteins demonstrating response to TGFβ [10 ng/ml] and successful
Smad4 depletion. C QRT-PCR of selected genes indicating alterations
in TGFβ response [10 ng/ml, 24 h].
Smad4 expression was completely depleted in NKC-II Smad4 k.o. cells, it remained
intact in Smad4 WT cells. Regardless of Smad4 status, cells responded to TGFβ
treatment with subsequent phosphorylation of recepter Smads. Snai1, a transcriptional
target of Smad4, was induced by TGFβ in the Smad4 WT clone, but failed to be
induced in the absence of Smad4. On mRNA level [Figure 13 C], we confirmed the
integrity of TGFβ response by consequent induction of the inhibitory Smad (Smad7)
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and the loss of Smad4 expression. We hereby confirmed successfull CRISPR/Cas9-
mediated Smad4 k.o. in murine primary NKC-II cells on DNA, mRNA and protein
level and demonstrated unbiased TGFβ response in both NKC-II Smad4 WT and k.o.
clones.
Characterizing the NKC-II clones comprised detailed analysis of functional conse-
quences of TGFβ response depending on the Smad4 status. As TGFβ is a known
accelerator of migration (Ciacci et al., 1993; Mythreye & Blobe, 2009; Takai et al.,
2012; Gao et al., 2014; Melzer et al., 2017), we assessed TGFβ-mediated migration
in a wound healing assay using live cell imaging [Figure 14 A]. Regardless of Smad4
expression, TGFβ treatment hastened the intrinsic migration speed in both clones.
Interestingly, the maximal migration distance covered by NKC-II Smad4 k.o. cells sig-
nificantly exceeded the Smad4 WT clone, ultimately leading to faster wound closure.
To figure out if that phenomenon was indeed an increased migrative capacity fostered
by TGFβ or a side effect of propagated cell growth, we determined the proliferative
capacity of CRISPR/Cas9 clones via cell counting [Figure 14 B]. In the observed time-
frame, there were no significant differences in proliferation detectable according to
Smad4 status. Importantly, this was confirmed by comparing CRISPR/Cas9 clones of
two additional PDAC cell lines [see Appendix Figure 32].
In addition, we aimed to identify the Smad4 clone’s ability to anchorage-independent
growth depending on TGFβ [Figure 14 C]. Essentially, Smad4 deficiency alone sig-
nificantly triggered colony formation in the soft agar assay. Additionally, TGFβ ad-
ministration further promoted clonal growth of NKC-II Smad4 k.o. cells while there
was no effect on Smad4 WT cells. Anchorage-independent growth is a hallmark of
carcinogenesis and is considered a characteristic feature of stem cells (Taddei et al.,
2012). Therefore, we assessed the stem cell capacity of both NKC-II clones via sphere
formation assay using the final sphere number and size distribution as readouts [Figure
14 D]. TGFβ treatment led to decreased sphere numbers in both clones, with NKC-II
Smad4 k.o. cells forming slightly more spheres compared to Smad4 WT. Importantly,
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the size of spheres differed extremely between clones. While Smad4 WT cells formed
small spheres that were turning bigger upon TGFβ application, NKC-II Smad4 k.o.
cells rather developed huge spheres independent of TGFβ. With the help of diverse





Figure 14 Smad4-dependent functional consequences of TGFβ treat-
ment. TGFβ was administered as 10 ng/ml. A Wound healing assay
in confluent, serum-starved NKC-II clones (n = 3). Migration was
retraced via live cell imaging by taking one picture per hour. B Prolif-
erative capacity was measured by cell counting every second day (n =
3). C Anchorage-independent growth was assessed via colony counting
in soft agar assay 7 d after seeding (n = 3). D Sphere formation in
low attachment plates was evaluated after 7 d cultivation (n = 3) by
counting and diameter measurement.
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functional assays we identified increased migrative and stem cell abilities in Smad4-
depleted NKC-II cells which were only partly determined by TGFβ treatment. In















































































































NKC-II: murine; KrasG12D; NFATc1-HA c.n.
A
B C
Figure 15 Smad4 dependency of nuclear NFATc1/Smad3 complex for-
mation. Co-IP experiments were conducted with nuclear lysates of
indicated cell lines utilizing HA-tagged NFATc1 as bait and confirm-
ing attached proteins via western blot. A Co-IP experiment including
both NKC-II clones subsequent to 24 h TGFβ exposition or serum
starvation only. B Knockdown of Smad3 confirms signal specificity
of Smad3 bands in co-IP experiments. C Reexpression of Smad4 in




To this point, we observed functional differences in NKC-II cells upon Smad4 deficiency.
Further, we utilized these cells to investigate NFATc1/Smad3 complex formation and
aimed to elucidate whether this transcription complex relies on the Smad4 status or
active TGFβ signaling, respectively. Therefore, we isolated nuclear extracts of NKC-II
Smad4 WT and k.o. cells to check for nuclear complex formation via co-IP utilizing
the HA-tagged NFATc1 as bait [Figure 15 A]. In Smad4 WT expressing cells, detected
Smad3 and Smad4 signal in co-IP samples was similar to measured background deter-
mined by IgG. Successful activation of the TGFβ pathway was controlled via pSmad3
detection in the input samples of both clones, respectively. However, only NKC-II
Smad4 k.o. lysates presented a strong signal of co-immunoprecipitated pSmad3 upon
TGFβ administration. Additionally, we performed a siRNA-mediated Smad3 knock
down with subsequent nuclear lysate isolation and co-IP to verify signal specificity
of the Smad3 protein band detection [Figure 15 B]. Indeed, we noticed strong reduc-
tion of co-immunoprecipitated Smad3 levels upon introduction of Smad3 silencing. To
confirm the observed Smad4 dependency of NFATc1/Smad3 complex formation, a full-
length FLAG-tagged Smad4 construct was reintroduced into NKC-II Smad4 k.o. cells
[Figure 15 C]. Nuclear lysates validated successful Smad4 protein expression in line
with reduced signal of co-immunoprecipitated Smad3 in FBS-supplemented cultiva-
tion medium. By using nuclear lysates of NKC-II clones in different co-IP approaches
and in line with data from our transgenic mouse model, we identified NFATc1/Smad3
complex formation preferentially in Smad4-deficient PDAC cells.
In our first co-IP experiments [Figure 15 A], we observed that TGFβ administration
fostered Smad3 phosphorylation and consequently promoted its complex formation
with NFATc1. However, NFATc1/Smad3 complexes were not strictly depending on
TGFβ as they also occurred in serum-deprived cells. In order to further explore if
TGFβ influences NFATc1/Smad3 complex formation, we isolated nuclear lysates of
NKC-II Smad4 k.o. cells that were treated with increasing concentrations of TGFβ
for 24 h subsequent to serum starvation [Figure 16]. Co-IP experiments revealed an













































































NKC-II Smad4 k.o.: murine; KrasG12D; NFATc1-HA c.n.
Figure 16 TGFβ dependency of nuclear NFATc1/Smad3 complex for-
mation. NKC-II Smad4 k.o. cells were serum-starved for 24 h prior to
administration of indicated TGFβ concentrations for another 24 h. Nu-
clear lysates were conducted to co-IP utilizing the HA-tagged NFATc1.
Complex partners were confirmed by western blot for indicated targets.
accompanied by a gradual increase of Smad3 phosphorylation. We demonstrated that
the complex assembly itself was not relying on TGFβ activity, but indicated that it
supported an increase in NFATc1/Smad3 complex formation.
With the establishment of Smad4 k.o. cells via CRISPR/Cas9-mediated genome edit-
ing in NKC-II cells, we accomplished to create a PDAC model system relying on the
same genetic background, thereby excluding artifacts of PDAC heterogeneity. This
enabled us to study Smad4 effects in cells with unaltered TGFβ response, reveal-
ing advances in migration, anchorage-independent growth, and sphere formation upon
Smad4 deficiency. Importantly, we demonstrated NFATc1/Smad3 nuclear complex
formation in Smad4-depleted NKC-II cells that is abrogated upon reintroduction of
Smad4. NFATc1/Smad3 complex assembly occurred irrespective of TGFβ administra-
tion.
Next, we aimed to investigate whether Nfatc1/Smad3 complex assembly was limited
to murine models of PDAC. To this end, we investigated Nfatc1/Smad3 complex for-
























































































































































Figure 17 NFATc1/SMAD3 complex assembly depends on SMAD4 de-
ficiency and oncogenic KRAS activation. A SMAD4-depleted
human BxPC3 cells were serum-starved prior to 24 h TGFβ treat-
ment. Nuclear lysates were conducted to co-IP studies utilizing en-
dogenous NFATc1 protein expression and visualized via western blot.
B SMAD4-depleted human PaTu8988t cells were transfected with
FLAG-tagged SMAD3 construct 24 h before isolation of nuclear frac-
tion. FLAG-based co-IP experiments displayed enrichment of co-
immunoprecipitated endogenous NFATc1 protein in western blot. C
PaTu8988t cells were transfected with FLAG-tagged SMAD3 ± HA-
tagged SMAD4 24 h prior to nuclear lysate extraction. Co-IP studies
utilizing the FLAG-tag checked for NFATc1/SMAD3 complex forma-
tion via western blot. D Primary human PDAC cells isolated from a
patient-derived xenograft were harvested for nuclear lysates. Subse-
quent co-IP experiments using endogenous SMAD3 as bait were dis-
played via western blot analysis.
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cells did not reveal co-immunoprecipitated Smad3 or pSmad3 bound to Nfatc1 despite
homozygous SMAD4 deletion [Figure 17 A]. As BxPC3 cells retain KRAS WT status,
we concluded that oncogenic KRAS activation is a prerequisite for Nfatc1/Smad3 com-
plex assembly. We next employed SMAD4-deficient PaTu8988t cells to study Smad3
complex formation by introducing a FLAG-tagged SMAD3 construct into the human
PDAC cells. Via co-IP studies with subsequent western blotting, we visualized ac-
cumulation of endogenous NFATc1 protein bound to SMAD3-FLAG [Figure 17 B].
Importantly, by co-transfection of FLAG-tagged SMAD3 and HA-tagged SMAD4, we
could demonstrate abrogation of co-immunoprecipitated NFATc1 bound to SMAD3,
confirming SMAD4 deficiency as a prerequisite for NFATc1/SMAD3 complex assembly
[Figure 17 C]. Ultimately, the question remained whether NFATc1/SMAD3 complexes
assemble in human patient tissue. Therefore, we chose a primary human PDAC cell line
which was expanded from patient-derived xenograft studies as part of a collaboration
with Prof. S. Hahn, Clinical Research Center, Ruhr-Universität Bochum and Prof. J.
Siveke, West German Cancer Center, University Hospital Essen [Figure 17 D]. Corre-
sponding sequencing data gathered in cooperation with the Institute of Human Genet-
ics, University Medical Center Göttingen, confirmed oncogenic KRAS activation and
homozygous loss of SMAD4 [data not shown]. Co-IP experiments using endogenous
SMAD3 expression validated binding of NFATc1 in primary, patient-derived PDAC
cells.
In this study, we employed patient data, patient-derived xenografts, established human
PDAC cell lines as well as murine primary cells and GEMMs of PDAC to investigate
conditions of NFATc1/SMAD3 complex formation. By utilizing both co-IP with en-
dogenous NFATc1 levels and overexpression as well as in situ PLA approaches, we
identified both oncogenic KRAS activation and homozygous SMAD4 depletion as pre-
requisites allowing for NFATc1/SMAD3 complex assembly. Surprisingly, activation of
TGFβ signaling was not a crucial trigger of nuclear transcription complex assembly,
but increased the proportion of phosphorylated SMAD3 bound to NFATc1 and further
promoted the protein interaction. Hence, we hypothesize that active TGFβ signal-
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ing plays a role in enhancing the transcriptional activity of nuclear NFATc1/SMAD3
complexes by encouraging DNA binding and preventing premature disassembly.
3.2 Targeting NFATc1/Smad3/cJun complexes as a
novel therapeutic approach in PDAC
In the second part, we focused on the identification of potential target genes as well
as regulated pathways and exploited therapeutic vulnerabilities that were associated
with Smad4 deficiency.
3.2.1 AP-1 proteins contribute to NFATc1/Smad3 complex
formation
To get a first hint regarding gene signatures jointly regulated by NFATc1 and Smad3,
we cooperated with Dr. S. Nagarajan, Cambridge Research Institute, University of
Cambridge for intersecting NFATc1 ChIPseq data derived from PDAC cells (Baumgart
et al., 2014) with SMAD3 ChIPseq data from mammospheres in presence or absence
of 0.1 nM TGFβ for 3 h (Tufegdzic Vidakovic et al., 2015) [Figure 18]. Interestingly,
in addition to jointly NFATc1/SMAD3 regulated genes, a fraction of genes was as-
sociated with an additional AP-1 binding motif (Angel et al., 1987), suggesting the
existence of joint transcription regulation by NFATc1/SMAD3/AP-1 complexes. Chen
et al. (2015) introduced NFATc1/AP-1 cooperativity in 61.8 % of all NFATc1 targets,
emphasizing the link between active epidermal growth factor receptor (EGFR) signal-
ing and NFATc1/cJun complexes in PDAC. Among the AP-1 family, cJun is unique
in its ability to positively regulate cell proliferation through the repression of tumor
suppressor genes (Shaulian & Karin, 2001), thus highlighting cJun as an interesting












Figure 18 NFATc1 forms transcription complexes with Smad3 and
AP-1 proteins. NFATc1 ChIPseq data were intersected with SMAD3
ChIPseq studies ± TGFβ. Peaks in NFATc1 ChIPseq were fre-
quently associated with AP-1 binding motifs, resulting in subgroups of
NFATc1/SMAD3 or NFATc1/SMAD3/AP-1 jointly regulated genes.
As cJun is a known Smad3 interacting protein (Zhang et al., 1998; Wong et al., 1999;
Dennler et al., 2000), we focused on investigating the interplay of NFATc1, Smad3
und cJun in PDAC cells [Figure 19 A]. Via co-IP studies, we confirmed the formation
of nuclear NFATc1/Smad3/cJun complexes in NKC-II Smad4 k.o. cells. Via siRNA-
mediated knock down of cJun and Smad3, we aimed to dissect whether interference
with one of the complex partners is sufficient to disassemble the whole transcription
complex. Accordingly, input samples served as knock down efficiency controls. As
expected, single knock down lead to a decrease of the respective co-immunoprecipitated
protein band. Interestingly, both single cJun or Smad3 knock down resulted in severe
decline of the other protein, implicating that cJun silencing also interferes with Smad3
binding to HA-tagged NFATc1. The differences in cJun binding to NFATc1 subsequent
to cJun knock down and Smad3 knock down, respectively, were clearly decreased with
a p-value of 0.084, suggesting that cJun is able to bind NFATc1 in absence of Smad3
albeit with decreased efficiency.
Next, we aimed to check if Nfatc1 proteins are indispensable for Smad3/cJun com-

























































































KPC Bl6 NFATc1 k.o.: murine; KrasG12D; p53R172C
B
Figure 19 cJun contributes to NFATc1/Smad3 complex formation. A
Smad3 and cJun knock down studies were combined with co-IP ex-
periments in NKC-II Smad4 k.o. cells. Western blot analysis re-
vealed alterations in nuclear NFATc1 complex assembly caused by
cJun and Smad3 knock down, respectively. Protein band intensity of
co-immunoprecipitated Smad3 and cJun was measured with FIJI and
normalized to respective HA-Tag signal (n = 3). B Nuclear lysates of
KPC Bl6 Nfatc1 k.o. cells ± Smad4 knock down were conducted to
co-IP experiments with subsequent western blot.
Nfatc1 k.o. for Smad4 knock down studies [Figure 19 B]. Nuclear lysates were con-
ducted to co-IP studies utilizing endogenous Smad3 protein levels. We hereby observed
enforced Smad3/cJun complex assembly subsequent to Smad4 knock down, while co-
immunoprecipitated Smad2 protein was indifferent to Smad4 expression levels. In
agreement with Zhang et al. (1998), our data confirm Smad3/cJun complex formation
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irrespective of Nfatc1 status, but in contrast, it provides evidence that Smad4 deficiency
severely enhances cJun binding to Smad3. However, this experimental approach does
not allow conclusions if Nfatc1 protein expression further supports Smad3/cJun com-
plex formation. Together, we identified the existence of Nfatc1/Smad3/cJun complexes
in PDAC and concluded that those nuclear transcription complexes are preferably as-
sembled in Smad4-deficient PDAC cells.
Investigating circumstances promoting nuclear NFATc1/Smad3/cJun complex forma-
tion was the first step to elucidate jointly regulated gene signatures and ultimately,
develop a targeted therapy approach to exploit PDAC vulnerabilities caused by Smad4
deficiency. Targeting NFATc1 is problematic as most inhibitors target upstream cal-
cineurin signaling which plays an important role in immune response and therefore
lacks a selective effect on tumor growth. The use of TGFβ inhibitors, or more spe-
cific Smad3 inhibitors, deprive us from exploiting tumor-suppressive TGFβ signaling,
which is an effective tool in restraining tumor growth (Hasselluhn et al., in revision).
In contrast, AP-1 proteins are downstream of the Mek/Erk signaling pathway, which
is fostered by oncogenic Kras activation (Johnson et al., 1996), thus representing an
interesting target in PDAC therapy.
Accordingly, we checked the efficacy of the established Mek1/2 inhibitor UO126 (Fa-
vata et al., 1998) in disrupting nuclear NFATc1/Smad3/cJun complexes [Figure 20].
Cells were maintained in normal growth medium prior to adding either 1 µM UO126
or the equivalent amount of DMSO for 1 h. The nuclear fraction was isolated and
tested in co-IP approaches for NFATc1/Smad3/cJun complexes. In NKC-II Smad4
k.o. cells, UO126 treatment led to severe disassembly of Smad3 and cJun proteins from
HA-tagged NFATc1 used as bait [Figure 20 A]. In accordance with knock down exper-
iments conducted in the same cells [Figure 19 A], we observed concomitant significant
loss of co-immunoprecipitated Smad3 and cJun proteins, respectively. To test whether
the transcription complex disrupting quality of UO126 could be reproduced in another




















































































































PaTu8988t: human; KrasG12D; Smad4 HD
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Figure 20 Mek inhibition by UO126 disrupts nuclear
NFATc1/Smad3/cJun complexes. Co-IP studies were con-
ducted in Smad4-deficient PDAC cells treated with 1 µM UO126 or
DMSO for 1 h prior to preparation of nuclear extracts. Decrease
of respective pErk1/2 signal in input samples serves as treatment
control. A HA-tagged NFATc1 was utilized for detecting co-
immunoprecipitated Smad3 and cJun via western blot. Protein band
intensity of co-immunoprecipitated Smad3 and cJun was measured
with FIJI and normalized to respective HA-Tag signal (n = 3). B
FLAG-based co-IP studies with subsequent western blotting of nuclear










NKC-II Smad4 k.o.: murine; KrasG12D; NFATc1-HA c.n.
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Figure 21 Mek inhibition by Trametinib disrupts nuclear
NFATc1/Smad3/cJun complexes. TGFβ-activated Smad4-
deficient NKC-II cells were treated with 5 nM Trametinib or DMSO
prior to nuclear lysate generation. Co-IP studies were conducted
utilizing HA-tagged NFATc1 as bait and visualized by western blot.
followed by inhibitor treatment [Figure 20 B]. 1 µM UO126 for 1 h effectively reduced
binding of endogenous NFATc1 and cJUN proteins to SMAD3-FLAG. Together, UO126
treatment studies revealed effective reduction of NFATc1/Smad3/cJun complexes in
both human and murine Smad4-deficient PDAC cells. This is in agreement with previ-
ous studies claiming that UO126 functionally antagonizes AP-1 transcriptional activity
(Favata et al., 1998; Duncia et al., 1998). However, the applied dose of UO126 exceeds
levels that can be employed for human PDAC patient therapy and thus was never
tested in clinical trials.
Therefore, we searched for a corresponding Mek inhibitor with a lower working concen-
tration that was already used in clinical trials and could be exploited for the disruption
of NFATc1/Smad3/cJun complexes in our system. Right now, the Mek1/2 inhibitor
Trametinib (Abe et al., 2011) is enrolled in 173 clinical trials, of which 8 deal with
pancreatic cancer, comprising 5 designated phase 2 trials. In a first step, we aimed
to reproduce NFATc1/Smad3/cJun complex disruption as a consequence of Mek1/2























Figure 22 Smad4 deficiency promotes Trametinib sensitivity in murine
PDAC cells. MTT experiments were conducted in quintuplicates in
a 96 well plate with 24 h Trametinib treatment using indicated concen-
trations and DMSO as a control. Prior to treatment and incubation
with indicated media, cells were serum-starved for 24 h. IC50 was cal-
culated from three independent experiments, respectively.
NKC-II Smad4 k.o. cells for Trametinib treatment studies with subsequent nuclear
extract isolation and co-IP experiments [Figure 21]. Subsequent to Trametinib ad-
ministration, decline of co-immunoprecipitated cJun and Smad3 signal was validated
despite of successful HA-Tag co-IP. These data emphasized that 5 nM Trametinib suf-
ficiently enforced the disassembly of nuclear NFATc1/Smad3/cJun complexes in the
context of active TGFβ signaling.
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In a second step, the efficacy of Trametinib was tested in increasing concentrations in
MTT assays subsequent to 24 h serum starvation in NKC-II clones [Figure 22]. This
approach comprised subsequent cultivation in different media, thereby enabling us to
check for differences in Trametinib response depending on nutrients and growth factors.
Trametinib treatment with continuous serum starvation did not lead to any differences
in cell vitality with regards to Trametinib concentration or Smad4 status of cells, respec-
tively. TGFβ-supplemented medium promoted significant differences between NKC-II
clones in Trametinib response from 5 nM onwards. IC50 calculations revealed significant
higher sensitivity of Smad4-deficient NKC-II cells towards the Mek1/2 inhibitor. Dose-
response studies in FBS-supplemented medium also promoted Trametinib efficacy in
Smad4-depleted cells. Interestingly, IC50 calculations revealed the same trend as mea-
sured in TGFβ-supplemented medium, but in general cells tolerated higher doses of
Trametinib.
3.2.2 Elucidation of NFATc1/Smad3/cJun regulated gene
signatures in PDAC
As the Mek1/2 inhibitor Trametinib showed to be an efficient tool to disrupt NFATc1/
Smad3/cJun complexes in Smad4 deficiency, we aimed to further scrutinize jointly
regulated gene signatures of the transcription complex via RNAseq. In our setup, we
included serum starvation prior to 24 h TGFβ and Trametinib treatment to exploit
alterations in genome-wide gene expression patterns [Figure 23 A]. Importantly, we
also included NFATc1-depleted samples to elucidate NFATc1 as a crucial member of
the transcription complex.
In parallel to RNA isolation, we harvested cotreated protein samples as treatment
controls [Figure 23 B]. Western blot analysis demonstrated reduced pErk1/2 levels as
Trametinib treatment control and confirmed activation of TGFβ signaling by robust
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Figure 23 Smad4 status determines Trametinib response in PDAC cells.
A Treatment scheme for RNAseq studies was composed of NFATc1
silencing or Trametinib treatment (5 nM) in the context of serum-
starved TGFβ-treated Smad4 WT and k.o. PDAC cells. B Protein
samples were harvested as treatment controls in parallel to RNA iso-
lation. Whole cell lysates were conducted to western blot analysis to
confirm Smad4 status, successful TGFβ stimulation, effective NFATc1
knock down and Trametinib treatment, respectively. C Treatment
controls for NFATc1 silencing and TGFβ treatment on mRNA level
were provided by qRT-PCR prior to sequencing (n = 3, respectively).
Peinado et al. (2003). Accordingly, Smad4 status of respective cells was confirmed and
NFATc1 depletion visualized. Analysis of protein pattern confirmed successful treat-
ments and were further complemented by analyzing the corresponding RNA samples
isolated in triplicates. We validated successful NFATc1 knockdown via qRT-PCR [Fig-
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ure 23 C]. Interestingly, Trametinib treatment led to decrease of NFATc1 expression
in Smad4 deficiency, while it increased in Smad4 WT cells. As additional treatment
control, we checked for Smad7 expression levels. Importantly, Smad7 expression was el-
evated in Trametinib-treated NKC-II Smad4 k.o. cells, suggesting abrogation of active
TGFβ signaling by the inhibitory Smad.
A
B
Figure 24 PCA plot of distinct RNAseq conditions. PCA plots were calcu-
lated as part of the quality control to assess similarities between repli-
cates and differences between conditions, and Smad4 status, respec-
tively. A PCA plot fo six distinct conditions, with Trametinib-treated
samples clustering separately according to Smad4 status. B Detailed
view on clustering of si ctrl and siNFATc1-treated samples in the con-
text of DMSO and TGFβ reveals increased impact of NFATc1 silenc-
ing in Smad4-depleted NKC-II cells. Abbreviations: NKC-II Smad4
wildtype (S4WT), NKC-II Smad4 knock out (S4ko), si ctrl DMSO
TGFβ (CDT), si ctrl Trametinib TGFβ (CTT), and siNFATc1 DMSO
TGFβ (NDT).
PCA plots were displayed to evaluate similarity among replicates and differences inbe-
tween conditions. Clustering of all six conditions revealed major differences between
Trametinib-treated samples opposed to their DMSO-treated counterparts (NKC-II si
ctrl Trametinib TGFβ versus si ctrl DMSO TGFβ or siNFATc1 DMSO TGFβ) and
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Figure 25 Smad4 deficiency alters tumor cell morphology and their in-
teractive potential. Significantly regulated genes in NKC-II Smad4
WT si ctrl DMSO TGFβ as opposed to Smad4 k.o. (log2foldchange
≥ 1.5, ≤ -1.5; q < 0.05) underwent GO analysis. A Comparison of
positively enriched molecular functions in Smad4 WT and Smad4 k.o.,
respectively. B Significantly regulated genes in both treatment groups
belong to different protein classes implicated in ECM modulation, cell
shape, cell adhesion, and cell-cell contacts.
NFATc1 silencing (NKC-II si ctrl DMSO TGFβ versus siNFATc1 DMSO TGFβ)
demonstrated an enhanced NFATc1 signature in Smad4-deficient NKC-II cells com-
pared to Smad4 WT [Figure 24 B]. Together, PCA plots showed strong similarity
among replicates and reproduced different treatments by clustering into six distinct
conditions accordingly. Prior to further analysis, a FPKM threshold > 5 was estab-
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lished, restraining the expressed genes in our RNAseq analysis to 39.7 % (9216/23 234
genes).
To correlate our RNAseq data to differences in the phenotypes of our mouse models,
we identified differentially regulated genes in Smad4 WT and Smad4-deficient NKC-
II cells in control condition (si ctrl DMSO TGFβ; log2foldchange ≥ 1.5, ≤ -1.5; q
< 0.05). Significantly regulated genes were further analyzed using GO tools [Figure
25]. In agreement with the phenotype observed in SKC fl/fl p48 mice as opposed
to KC p48, we demonstrated positive enrichment of molecular functions involved in
cell presentation, cell contacts, and ECM adjustment. This is further supported by
differences observed in positively enriched protein classes [Figure 25 B], suggesting
that Smad4 WT cells focus on adhesion and binding to neighboring cells while Smad4
deficiency results in alterations of the cytoskeleton and loss of cell-cell contacts. Thus,
we propose that the cell identity is decisively depending on the Smad4 status of the
respective PDAC cell.
Secondly, we aimed to decipher NFATc1/Smad3/cJun-driven gene signatures in Smad4-
depleted PDAC cells. To stratify respective gene sets, we benefitted from the thor-
ough analysis of complex formation dependencies. As (i) Smad3/cJun complexes were
formed regardless of NFATc1 expression [Figure 19 B], (ii) Smad3/cJun assembly was
also observed in Smad4 WT status [Figure 19 B] and (iii) Mek inhibition was suffi-
cient to disrupt Smad3/cJun protein binding [Figure 20 B], we needed to differentiate
between NFATc1/Smad3/cJun complexes and Smad3/cJun complexes. Therefore, we
focused on targets influenced by both NFATc1 silencing and Trametinib treatment in
Smad4 deficiency. Consequently, we filtered for genes whose expression levels were
modulated by Trametinib (NKC-II Smad4 k.o. si ctrl DMSO TGFβ versus si ctrl
Trametinib TGFβ; log2foldchange ≥ 0.75, ≤ -0.75; q < 0.05) as well as NFATc1
knockdown (NKC-II Smad4 k.o. si ctrl DMSO TGFβ versus siNFATc1 DMSO TGFβ;
log2foldchange ≥ 0.75, ≤ -0.75; q < 0.05). The identified genes were overlayed in a
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Figure 26 NFATc1/Smad3/cJun complexes interfere with proliferation,
cell motility and ECM composition. A Venn diagram illustrating
the identification of 93 genes accounting for the subset of potential
NFATc1/Smad3/cJun targets. B Z score heatmap covering the ex-
pression levels of 93 potential complex targets and their regulation
in Smad4 WT and deficiency upon Trametinib administration and
NFATc1 silencing, respectively. C GO analysis of pathways enriched
for potential NFATc1/Smad3/cJun targets.
Smad4 WT si ctrl DMSO TGFβ versus si ctrl Trametinib TGFβ; log2foldchange ≥
0.75, ≤ -0.75; q < 0.05) to exclude false positive hits [Figure 26 A]. Hence, we concluded
that the 93 genes regulated by Trametinib, and NFATc1 in Smad4 deficiency, but not
influenced by Trametinib in Smad4 WT situation represent the fraction of potential
NFATc1/Smad3/cJun targets. The 93 potential NFATc1/Smad3/cJun targets were
visualized by z score in a heatmap [Figure 26 B], demonstrating on the one hand huge
differences in si ctrl DMSO TGFβ-treated samples depending on the Smad4 status
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and on the other hand increased Trametinib response of respective genes in Smad4 de-
ficiency. To obtain insights into their functional relevance in Smad4-deficient PDAC,
we performed GO analysis with respective target genes [Figure 26 C]. While most of
the biological processes deal with cellular growth, there are also signatures implicated
in structural changes of the cell like cell adhesion, migration, and invasion.
Next, we aimed to determine whether NFATc1/Smad3/cJun complexes could be the
driving force behind the dismal prognosis of Smad4-deficient PDAC. We compared
our RNAseq data to publically available datasets of unfavorable and favorable genes
in PDAC (Cancer Genome Atlas Research Network et al., 2013; Uhlen et al., 2017)
and demonstrated for NKC-II Smad4 k.o. cells a switch from significantly enriched
dismal prognostic genes in si ctrl DMSO TGFβ to induction of favorable prognostic
gene patterns upon Trametinib treatment (si ctrl Trametinib TGFβ) [Figure 27 A].
NKC-II Smad4 WT cells in si ctrl DMSO TGFβ condition significantly correlated
with unfavorable prognosis (NES = 1.35, FDR = 0.051), but the Trametinib-induced
switch to favorable gene expression was only confirmed in Smad4 deficiency (NKC-
II Smad4 WT si ctrl Trametinib TGFβ: NES = −1.08, FDR = 0.460). In total,
415 out of 669 genes implicated in unfavorable prognosis were expressed in NKC-II
cells (FPKM > 5). We performed an overlay with the 93 previously determined po-
tential NFATc1/Smad3/cJun targets and identified 9 common genes downregulated
upon Trametinib and NFATc1 knockdown in the context of TGFβ, respectively. Fi-
nally, we utilized the UniProt database (UniProt Consortium, 2018) to connect po-
tential NFATc1/Smad3/cJun targets to their respective function [Figure 27 B]. Via
qRT-PCR, we validated a selection of genes associated with DNA replication [Figure
27 C], confirming decrease of expression levels upon NFATc1 depletion, and Trametinib
treatment in Smad4 deficiency. Transcription of the targets cyclin-dependent kinases
regulatory subunit 1 (Cks1b), fibroblast growth factor-binding protein 1 (Fgfbp1), and
minichromosome maintenance complex component 4 (Mcm4) did not decrease upon
Trametinib administration in Smad4 WT cells. Importantly, none of the 93 potential
NFATc1/Smad3/cJun target genes was associated with favorable prognosis in PDAC.
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A NKC-II Smad4 k.o. si ctrl DMSO TGFβ versus                    si ctrl Trametinib TGFβ
FDR = 0.064 FDR = 0.123NES = 1.77 NES = -1.57
B C
Ldlr Tuba1c
Cdc20 Cks1b E2f1 
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Figure 27 NFATc1/Smad3/cJun complex disruption interferes with dis-
mal prognostic factors. A Alignment of unfavorable and favor-
able prognostic genes in PDAC with Smad4-deficient RNAseq data
by GSEA revealed induction of favorable gene pattern upon Tram-
etinib treatment in TGFβ-induced cells. B Overlay of unfavorable
prognostic genes with previously identified NFATc1/Smad3/cJun tar-
gets produced 9 jointly regulated genes. Most of them were ei-
ther associated with proliferation or ECM as defined by UniProt
database. C Validation of NFATc1/Smad3/cJun target selection im-
plicated in promoting dismal outcome via qRT-PCR (n = 3). Ab-
breviations: cell division cycle protein 20 homolog (Cdc20), cyclin-
dependent kinases regulatory subunit 1 (Cks1b), collagen alpha-1 (VII)
chain (Col7a1), E2f transcription factor 1 (E2f1), fibroblast growth
factor-binding protein 1 (Fgfbp1), low-density lipoprotein receptor
(Ldlr), minichromosome maintenance complex component 4 (Mcm4),







Figure 28 Smad4 deficiency enhances Gemcitabine tolerance in murine
PDAC cells. A MTT experiments were conducted in quintuplicates
in a 96 well plate with 72 h Gemcitabine treatment in increasing con-
centrations. IC50 was calculated from 8 independent experiments, re-
spectively. B NKC-II clones were seeded in a 6 well plate and treated
with indicated Gemcitabine concentrations for 48 h prior to trypsiniza-
tion. Subsequent to Annexin V and propidium iodide staining, cells
were conducted to flow cytometric measurement. Data from three
independent experiments were analyzed by FlowJo software and the
apoptotic fraction normalized to their control samples. C MTT assay
in quintuplicates comprising 48 h Gemcitabine treatment. For the last
24 h, Trametinib was added in indicated concentrations.
The top two hits of biological processes driven by potential NFATc1/Smad3/cJun tar-
gets were implicated in nucleoside and nucleotide metabolism [Figure 26 C]. As the
standard of care for non-resectable, metastatic pancreatic cancer still relies on the nu-
cleoside analog Gemcitabine in most cases (Ellenrieder et al., 2016), Smad4-dependent
alterations of nucleoside metabolism are of particular interest. Subsequent studies
using different CRISPR/Cas9 clones revealed that Smad4 deficiency was universally
associated with increased tolerance against the tested nucleoside analogs Gemcitabine
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and AraC [Figure 28 A, Appendix Figure 33]. Accordingly, Annexin V/propidium
iodide staining with subsequent flow cytometry demonstrated that 48 h Gemcitabine
treatment result in lower apoptosis rates in Smad4 deficiency compared to Smad4 WT-
expressing NKC-II cells [Figure 28 B]. Vice versa, we tested if induced Gemcitabine
resistance by long-term exposition to increasing Gemcitabine concentrations is me-
diated by Smad4 silencing [Appendix Figure 34]. We could not detect alterations is
Smad4 protein or mRNA expression [Appendix Figure 34 A + B], thus concluding that
induced Gemcitabine tolerance is either realized via regulation downstream of Smad4
or via completely different mechanisms.
Combined treatment approaches aimed to elucidate if Trametinib administration sen-
sitized Smad4-deficient cells for Gemcitabine treatment. Indeed, we demonstrate im-
proved chemoresponse or resensitization of NKC-II Smad4 k.o. cells upon treatment
with Gemcitabine in levels below IC50 followed by Trametinib treatment in sub-IC50
concentrations [Figure 28 C]. Note that combined Gemcitabine and Trametinib treat-
ment were conducted in normal cultivation medium preventing disturbances in cell pro-
liferation. Importantly, sole Trametinib administration and combined treatment was
ineffective in NKC-II Smad4 WT cells. Thus, via dose-response studies of Trametinib
and Gemcitabine in NKC-II clones, we could validate increased therapeutic response
to combined Gemcitabine and Trametinib treatment caused by Smad4 depletion.
In order to elucidate how loss of Smad4 caused increased tolerance to nucleoside
analogs, we employed our RNAseq data to decipher altered gene signatures in NKC-II
Smad4 k.o. cells that conveyed increased Gemcitabine tolerance compared to Smad4
WT cells. As we observed increased Gemcitabine susceptibility in Smad4-deficient
cells subsequent to Trametinib treatment [Figure 28 C], we filtered for significantly
altered genes (log2foldchange ≥ 1.5, ≤ -1.5; FPKM > 5) in NKC-II Smad4 k.o. si
ctrl DMSO TGFβ versus si ctrl Trametinib TGFβ treated samples and displayed the
regulated genes as z score means throughout all conditions via heatmap [Figure 29 A].
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Figure 29 Trametinib administration restores Gemcitabine susceptibil-
ity. A Mean of replicates displayed as z score heatmap filtered
for significant alterations between NKC-II Smad4 k.o. DMSO and
Trametinib-treated conditions (log2foldchange ≥ 1.5, ≤ -1.5; FPKM >
5). B FPKM count normalized to NKC-II Smad4 WT si ctrl DMSO
TGFβ for genes implicated in Gemcitabine metabolism (n = 3, re-
spectively). C Gene expression levels for Gemcitabine metabolizing
enzymes evaluated by qRT-PCR (n = 3). Abbreviations: cytidine
deaminase (Cda), deoxycytidine kinase (Dck), deoxycytidylate deam-
inase (Dctd), 5’(3’)-deoxyribonucleotidase, cytosolic type (Nt5c),
cytosolic purine 5’-nucleotidase (Nt5c2), cytosolic 5’-nucleotidase 3A
(Nt5c3), ribonucleoside-diphosphate reductase large subunit (Rrm1),
and equilibrative nucleoside transporter 1 (Slc29a1).
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samples depending on Smad4 status, Trametinib administration led to an astonishing
approximation of the gene regulation pattern in Smad4 WT and k.o. condition (si ctrl
Trametinib TGFβ). This harmonization was in line with increased Gemcitabine re-
sponse detected after Trametinib treatment in Smad4-deficient cells. In addition, we
compared our RNAseq data to a gene list comprising important mediators of Gemci-
tabine and AraC metabolism provided by Li et al. (2008). 9 out of 17 genes met the
FPKM threshold (52.9 %) and their FPKM expression levels normalized to NKC-II
Smad4 WT si ctrl DMSO TGFβ were displayed [Figure 29 B]. Smad4 deficiency led to
enhanced expression of cytidine deaminase (Cda), deoxycytidylate deaminase (Dctd),
cytosolic purine 5’-nucleotidase (Nt5c2), ribonucleoside-diphosphate reductase large
subunit (Rrm1), and ribonucleoside-diphosphate reductase subunit M2 (Rrm2) tran-
scripts, respectively. Of note, Slc29a1 encodes for a transporter enabling cellular uptake
of Gemcitabine, representing the only nucleoside transporter verifiably transcribed in
our PDAC cells. All other genes are directly involved in Gemcitabine metabolism,
except for Rrm1 and Rrm2, respectively.
Based on these results, we identified four promising candidates for increased Gemcita-
bine tolerance in Smad4 deficiency that could be abrogated by Trametinib treatment
and validated their regulation in qRT-PCR experiments [Figure 29 C]. The enzymes
Cda and Dctd directly interfere with Gemcitabine metabolism, enforcing premature
degradation with subsequent transfer out of the cell, while Rrm1 and Rrm2 together
catalyze the biosynthesis of deoxyribonucleotides. The latter compete with phospho-
rylated Gemcitabine in DNA strand incorporation (Tanaka et al., 2010). Thus, we
identified candidate genes whose upregulation in Smad4-deficient PDAC cells might
convey increased Gemcitabine tolerance which could be counteracted by supplemen-
tary Trametinib treatment. Importantly, Rrm2 was previously identified as one of
the potential NFATc1/Smad3/cJun targets implicated in dismal prognosis, suggest-
ing that oncogenic NFATc1/Smad3/cJun-driven signatures contributed to increased
Gemcitabine tolerance in Smad4-deficient PDAC cells.
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Our RNAseq approach revealed signatures of potential NFATc1/Smad3/cJun targets
being involved in triggering an unfavorable prognosis in PDAC patients, alteration of
the tumor microenvironment, adaptation of cell morphology towards a more aggres-
sive and invasive phenotype, and impairment of nucleoside analog-based cytotoxicity.
These features corresponded with the hallmarks of Smad4-deficient PDAC identified in
our mouse model. Importantly, disruption of nuclear NFATc1/Smad3/cJun complexes
by Mek inhibitor Trametinib restored Gemcitabine response and altered the transcrip-






4.1 Smad4 deficiency in pancreatic cancer favors
invasiveness and aggressiveness of disease
Since the discovery of the tumor suppressor gene Smad4 by Hahn et al. (1996b), its
pivotal role in pancreatic cancer exceeds against other cancer entities. Loss of Smad4
occurs in half of all invasive PDAC patients (Wilentz et al., 2000a) and is associated
with dismal prognosis, thus defining the subgroup of Smad4-depleted PDAC as an
interesting target in precision medicine. Elucidating the mechanisms behind aggressive,
tumor-promoting gene signatures promoted by loss of Smad4 is an important step
in understanding cancer progression and thus development of therapeutic approaches
exploiting cancer vulnerabilities. Patient stratification is a first step in the direction of
personalized medicine, allowing to screen a patient cohort for specific genetic markers
to ensure tailored treatment regimes.
Loss of Smad4 in PDAC is associated with decreased patient survival and increased
metastatic spread (Shin et al., 2017), characterizing the Smad4 status as a prognostic
factor in human PDAC. The common Smad has a pivotal role in the TGFβ pathway
and its depletion is discussed to mediate the switch from tumor-suppressive to onco-
genic TGFβ signaling (Zhang et al., 1997). However, the exact mechanism on how
the TGFβ cascade is exploited for tumor promotion remains elusive. We hypothe-
sized that receptor Smads form alternative transcription factor complexes in absence
of Smad4, regulating differential gene signatures. In this study, we first identified nu-
clear NFATc1/Smad3/cJun transcription factor complexes in PDAC and scrutinized
conditions facilitating or abrogating this complex formation. We demonstrated that
Smad4 deficiency is crucial to allow NFATc1/Smad3/cJun complex assembly in various
human and murine PDAC cell lines. This was supplemented by murine in vivo PLA
studies, confirming the rise of Nfatc1/Smad3 signal upon homozygous loss of Smad4.
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Moreover, we discovered that the transcription complex is depending on oncogenic Kras
activation, thus limiting its occurrence to Kras-mutated PDAC as opposed to healthy
pancreatic tissue and scarce Kras-independent PDAC. In this work, we aimed to com-
prehend features of Smad4-deficient PDAC by studying pancreatic carcinogenesis and
metastasis in an in vivo model accompanied by functional in vitro assays utilizing
CRISPR/Cas9-mediated genome editing to establish Smad4 WT and k.o. clones with
similar genetic background.
4.1.1 Smad4 depletion cooperates with oncogenic Kras activation
in strong acceleration of PDAC formation
The SKC fl/fl p48 mouse model faithfully recapitulated severe reduction of life ex-
pectancy in comparison to Smad4 WT-expressing KC p48 mice as already observed
for human PDAC patients from TCGA database. Increased aggressiveness of disease
was reproduced by enforced initiation of preneoplastic lesion formation and early tu-
morigenesis. The enhanced metastatic burden observed in SKC fl/fl p48 mice is in
agreement with patient autopsy data provided by Iacobuzio-Donahue et al. (2009) and
resected human PDAC biopsies by Shin et al. (2017). There was no significant correla-
tion between Smad4 status and PDAC stage for the patient cohort of TCGA [data not
shown], while homozygous Smad4 depletion resulted in exclusively low PDAC stage
(G1) in our GEMM which is supported by previous data of Vincent et al. (2012). This
is in contradiction to proposed acceleration of PDAC invasiveness which suggested in-
creased dedifferentiation featured by loss of Smad4. We observed excessive gain of
pancreas weight in a short period of time covering the age of approximately 6 to 12
weeks. At the same time, respective SKC fl/fl p48 mice suffered from a drastic loss of
body weight. We suggest that premature death due to extreme tumor burden impaired




In agreement with Izeradjene et al. (2007), we utilized the p48-Cre recombinase to
target both KrasG12D as well as heterozogous or homozygous Smad4 depletion to the
pancreas. The Pdx1-Cre recombinase used by Kojima et al. (2007) in the context
of Smad deficiency can lead to severe extrapancreatic effects, while p48-Cre is more
tightly confined to the pancreas (Offield et al., 1996; Hingorani et al., 2005; Izeradjene
et al., 2007; Gades et al., 2008). In contrast to Izeradjene et al. (2007), we observed sig-
nificant decrease of lifespan of mice bearing Smad4 haploinsufficiency (SKC fl/+ p48)
compared to Smad4 WT (KC p48). We employed 20 individuals of each genotype
for our survival studies while insignificant results of Izeradjene et al. (2007) might be
explained by the small number of KC p48 animals (KC p48: n = 6; SKC fl/+ p48:
n = 22). In addition, homozygous Smad4 depletion in the context of oncogenic Kras
activation (SKC fl/fl p48) reduced survival to 4.2 months in our study as opposed to 8
months (n = 18) disclosed by Izeradjene et al. (2007). Importantly, our SKC fl/+ p48
and SKC fl/fl p48 models rely on the same GEMMs (Yang et al., 2002; Hingorani
et al., 2003), proposing that our end-point criteria were more strictly defined as in the
previous study by Izeradjene et al. (2007).
The second hit theory by Yachida & Iacobuzio-Donahue (2013) implicated that in hu-
man PDAC, genetic inactivation of TP53 in advanced PanIN stage is a prerequisite for
SMAD4 deficiency in established PDAC. As our mouse model was based on Tp53 WT,
the decisive genetic background for dedifferentiated PDAC might have been neglected.
Studies by Whittle et al. (2015) combining oncogenic Kras activation and homozygous
Smad4 depletion with Tp53R172H/+ under pancreas-specific p48-Cre demonstrated no
additional decrease in mouse lifespan (125 days median survival versus 129 days in our
SKC fl/fl p48 mice). However, Whittle et al. (2015) described the occurrence of ded-
ifferentiated areas in their GEMM, thereby suggesting that our SKC fl/fl p48 model
retained well-differentiated PDAC based on Tp53 WT status.
In addition, Singh et al. (2015) demonstrated that Tp53 mutation in the KrasG12D;
p53R172C/+; pdx-Cre (KPC) model and human PDAC is insufficient in driving ded-
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ifferentiation and is not correlated to higher tumor grading. Thus, they introduced
NFATc1 as a major driver of dedifferentiation in the context of Tp53 mutation. In our
GEMMs, we did not systematically assess NFATc1 abundance via IHC. Instead, we
determined NFATc1 expression levels in primary PDAC cell lines isolated from tumor-
bearing mice of respective genotypes, revealing only weak NFATc1 signal [data not
shown]. We conclude that highly differentiated PDAC observed in SKC fl/fl p48 mice
relies at least partly on low NFATc1 activity. This is in agreement with Diaferia et al.
(2016) describing strong NFATc1 signal as a hallmark of high-grade, undifferentiated
PDAC cells. On the molecular level, NFATc1-dependent transcription introduces in-
flammatory and proliferative signatures in PDAC (Buchholz et al., 2006). Importantly,
NFATc1 preferably cooperates with additional transcription factors for gene regulation
(Loh et al., 1996; Chen et al., 1998; Baumgart et al., 2014). Although Smad3/cJun
complexes are already described by Zhang et al. (1998), the participation of the inflam-
matory transcription factor NFATc1 as well as the promoted assembly upon Smad4
deficiency identified in our study add new aspects to the proposed transcription com-
plex. As the function of cJun is highly context-dependent (Eferl & Wagner, 2003),
the introduction of an inflammatory tumor environment by NFATc1 and activated
TGFβ signaling (Ben-Neriah & Karin, 2011; Baumgart et al., 2014) adjust the broad
spectrum of cJun-regulated genes to their full oncogenic potential. Consequently, trig-
gering NFATc1 expression by an inflammatory insult like caerulein could result in more
dedifferentiated PDAC formation.
4.1.2 Advantages of CRISPR/Cas9-mediated Smad4 knock out in
PDAC research
In this work, investigating functional implications of Smad4 deficiency in pancreatic
cancer in vitro relied on comparison of Smad4 WT and k.o. clones generated by
CRISPR/Cas9-mediated genome editing. Although there has been a lot of research
identifying Smad4-dependent TGFβ functions in PDAC (Schwarte-Waldhoff et al.,
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2000; Duda et al., 2003; Subramanian et al., 2004; Jonckheere et al., 2004; Yasutome
et al., 2005; Jazag et al., 2005; Bera et al., 2013; Leung et al., 2013; Fullerton et al.,
2015) this new technique offers a novel approach to elucidate contradictory data pub-
lished by other groups. In the past, gene silencing of Smad4 was exploited to scrutinize
Smad4-dependent TGFβ signaling and functions (Jazag et al., 2005; Bera et al., 2013;
Leung et al., 2013). In contrast to the status observed in patient tissue, where Smad4
is either present or completely absent in epithelial PDAC cells, knock down experi-
ments maintain residual Smad4 expression which can lead to undesired cross reactions
or prevent the establishment of gene signatures relying on total Smad4 deficiency. Ac-
cordingly, we did not employ Smad4 knock down experiments in this work if avoidable,
allowing us to remain closer to the human PDAC situation. Secondly, established
human SMAD4-deficient PDAC cell lines were exploited in the context of SMAD4
overexpression studies to recapitulate alterations in TGFβ response due to SMAD4
status (Schwarte-Waldhoff et al., 2000; Duda et al., 2003; Subramanian et al., 2004;
Jonckheere et al., 2004; Yasutome et al., 2005; Fullerton et al., 2015), leading to consid-
erable discrepancies in conclusions. Long-term adaptations to SMAD4 depletion might
lead to accumulation of additional mutations and alterations of chromatin landscape,
resulting in inconsistencies observed in the aforementioned literature. Therefore, rein-
troduction of SMAD4 constructs might not lead to reestablishment of conventional
TGFβ signaling. In our experimental setup, Smad4 overexpression studies were only
used for investigating conditions favoring transcription complex assembly. Here, we
focused on Smad4 protein expression traced by western blot, regardless of the up-
stream signaling pathways. Thirdly, established human PDAC cell lines with known
SMAD4 status were compared among each other (Duda et al., 2003; Subramanian
et al., 2004). Thereby, huge variations of the genetic background of each cell line are
neglected which potentially shape Smad4-dependent signatures. As pancreatic cancer
is characterized by its extreme genetic heterogeneity, this procedure elucidated robust
SMAD4-dependent pathways and functions but might also lead to false-positive find-
ings were SMAD4 deficiency might be cooperating with TP53 and KRAS mutations
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in driving certain gene signatures. Importantly, in these models, functional relevance
of SMAD4 in active TGFβ signaling might be missed due to data inconsistency.
The CRISPR/Cas9-mediated Smad4 depletion offers the unique chance to compare
Smad4-dependent functions and gene signatures in cells harboring the same genetic
background. We established CRISPR/Cas9-derived Smad4 k.o. clones and their respec-
tive Smad4 WT counterparts in two murine and one human PDAC cell line, thereby
covering different genetic backgrounds. Importantly, all cellular systems relied on onco-
genic Kras activation as a major driver of pancreatic carcinogenesis. We identified nu-
clear NFATc1/Smad3/cJun complexes exclusively in Smad4-deficient PDAC, thereby
confirming our hypothesis of alternative Smad3 binding partners in Smad4 deficiency.
Smad3 and Smad4 interact via their conserved carboxy-terminal mad homology (MH2)
domains which are also used for further association with DNA binding proteins and
transcriptional activators (Zhang et al., 1997; Attisano & Wrana, 2000). The amino-
terminal MH1 domain autoinhibits the MH2 domain, mediates DNA binding and also
promotes higher order complex assembly with additional DNA-binding partners (Atti-
sano & Wrana, 2000). We hypothesized that NFATc1/Smad3 interaction is mediated
via MH2 domain, offering a potential explanation of NFATc1/Smad3 complex assem-
bly exclusively in Smad4-deficient PDAC and suggesting comparably stronger binding
affinity of Smad4 and Smad3 proteins. However, this hypothesis could be tested in
future experiments by introducing a Smad4 construct only covering the MH2 domain
in Smad4-depleted PDAC cells and investigation of potential NFATc1/Smad3 complex
disruption.
In this work, we only commented on the influence of NFATc1 in shaping Smad3-
dependent transcription without ruling out the possibility of other transcription factors
hijacking Smad3 as a complex partner in the context of Smad4 depletion. However,
without claiming to disclose all potential Smad3 binding partners in Smad4 depleted
PDAC, we cannot draw any conclusions on the importance of NFATc1 in relation to
other alternative binding partners for Smad3. Thus, we focus on NFATc1/Smad3/cJun-
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mediated transcription promoting oncogenic gene signatures in Smad4 deficiency with-
out assigning every phenotypical feature observed upon loss of Smad4 to this transcrip-
tion complex.
To determine conditions beneficial for nuclear NFATc1/Smad3/cJun complex assem-
bly, the majority of experiments conducted in this work relied on murine NKC-II
Smad4 WT and k.o. clones. Conditional nuclear HA-tagged NFATc1 facilitated co-IP
studies and, in agreement with Baumgart et al. (2014) and Singh et al. (2015), led
to an aggressive phenotype recapitulating invasive PDAC in vitro. Consequently,
RNAseq analyses in TGFβ-treated NKC-II clones revealed significant induction of
unfavorable prognostic gene signatures in PDAC irrespective of Smad4 status (Can-
cer Genome Atlas Research Network et al., 2013; Uhlen et al., 2017). However, we
identified a potential subset of genes related to dismal prognosis differentially induced
by NFATc1/Smad3/cJun complexes in Smad4 deficiency. Those genes were not only
implicated in driving proliferation but also ECM modulation, synergizing in driving tu-
mor growth. The restrictions used to narrow down signatures of NFATc1/Smad3/cJun
complexes in Smad4 deficiency relied on the conditions identified by co-IP approaches,
thus ensuring involvement of the three transcription factors in the regulation of iden-
tified genes. However, this RNAseq approach did not allow any spatial or temporal
resolution on transcription factor binding to DNA. Future ChIP experiments could
contribute to the definition of DNA regions were NFATc1, Smad3, and cJun bind and
regulate their target gene expression in a transcription complex.
In this study, we failed to define the importance of activated TGFβ signaling for
NFATc1/Smad3/cJun transcription complex formation. We detected an increase in
co-immunoprecipitated Smad3 to NFATc1 subsequent to TGFβ administration which
was accompanied by increasing shares of Smad3 phorsphorylation at the carboxyl ter-
minal serine residues mediated by TβR-I (Zhang et al., 1996). However, Smad3 is
located predominantly in the nucleus (Chen et al., 1996; Zhang et al., 1997; Yasutome
et al., 2005) independent of its phosphorylation status. We proposed that activated
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TGFβ signaling fostered Smad3-dependent transcription and thus the transcriptional
output of the whole NFATc1/Smad3/cJun complex. Importantly, the relevance of di-
verse Smad3 phosphorylation sites in shaping its target gene regulation (Kretzschmar
et al., 1999; Sekimoto et al., 2007) while not affecting DNA binding affinity (Zawel et al.,
1998) has already been described. Future investigations dealing with Smad4-dependent
alterations of Smad3 phosphorylation occupancy could elucidate the molecular mech-
anisms behind gene signature variations as a consequence of Smad4 deficiency.
Assessing functional implications of Smad4 depletion using CRISPR/Cas9 clones in
vitro aimed to comprehend features of Smad4-deficient PDAC observed using GEMMs
in vivo. In a first attempt, we aimed to elucidate data discrepancies (Duda et al.,
2003; Subramanian et al., 2004; Jazag et al., 2005) regarding the role of Smad4 in
TGFβ-mediated migration. Thereby, we ensured that TGFβ response upstream of
Smad4 was unaffected in our CRISPR/Cas9 clones. We confirmed TGFβ-mediated
increase in migration speed in both Smad4 WT and k.o. cells and could demonstrate
at the same time that the migrative capacity of Smad4-deficient cells exceeded their
respective counterpart. Cell migration is a complex process based on iterated detach-
ing and reattaching steps combined with alterations of cell polarity and cytoskeletal
rearrangement (Dreymueller et al., 2017). Our RNAseq data suggested involvement of
NFATc1/Smad3/cJun complexes in driving genes associated with cytoskeletal organi-
zation, thus providing a potential link how increased migrative potential was promoted
in Smad4 deficiency. However, effective migration potential is one crucial prerequisite
of metastasis formation, as PDAC cells have to leave their original cell compound and
enter vessels to eventually settle down at distant sites like the liver tissue. Our in vitro
and in vivo data agreed in supporting the idea of increased metastasis formation by
accelerated migration in Smad4 deficiency.
In the migration assay, we kept cells after reaching confluency under constant serum
starvation to prevent proliferation interfering with intrinsic migrative power. Still,
we aimed to assess the Smad4-dependent proliferative capacity in our system. In all
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CRISPR/Cas9 cells, there was no difference in proliferation of clones, thereby excluding
cellular growth as an interfering factor in migration assays. This robust proliferation
rate regardless of Smad4 status in vitro was counterintuitive regarding the extreme
tumor growth in SKC fl/fl p48 mice in in vivo. Investigating the PDAC composition
by Masson’s trichrome and IF stainings demonstrated that the epithelial tumor cells
only represented a minor fraction of total pancreatic tissue. Importantly, the stromal
compartment was significantly increased in SKC fl/fl p48 mice compared to KC p48 or
SKC fl/+ p48 mice. Excessive fibrosis caused by Smad4 depletion was already demon-
strated by other laboratories (Kojima et al., 2007; Garcia-Carracedo et al., 2015). This
is in agreement with Liu et al. (2017) demonstrating cancer-associated fibroblasts hi-
jacking cancer cells for dissemination from the primary tumor site. Based on Shintani
et al. (2006), we suggested that the enhanced collagen deposition in SKC fl/fl p48
mice accounts for the increased hepatic metastatic spread in low-grade, differentiated
PDAC. Gene signatures associated with Smad4 deficiency as opposed to Smad4 WT
identified by RNAseq with subsequent GO analysis revealed immense differences in
cell morphology, proposing that important cell characteristics are decisively depend-
ing on Smad4 status. Importantly, those structural alterations were complemented by
features comprising the interaction with surrounding tumor cells and stroma. GO anal-
ysis suggested that Smad4 deficiency in PDAC cells led to differential manifestation of
cell-cell contacts and cell adhesion, potentially facilitating metastatic spread in vivo.
In addition, our RNAseq results proposed Smad4-dependent alteration of ECM com-
position by affecting the secretion of chemoattractants. Smad4-deficient PDAC cells
might retain their differentiated phenotype but alter their tumor microenvironment,
thus attracting fibroblasts contributing to hepatic metastasis.
Another prerequisite for distant metastasis formation is anchorage-independent growth
(Taddei et al., 2012). Only malignant cancer cells resist against anoikis, a special
form of apoptosis caused by loss or alterations of cell adhesion (Frisch & Francis,
1994). Yasutome et al. (2005) already described faster cell adhesion upon restoration
of SMAD4 in BxPC3 cells. We observed the same phenomenon while subcultivating
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CRISPR/Cas9 clones and identified the corresponding gene signatures in our RNAseq
analysis. In addition, we confirmed the crucial role of Smad4 deficiency in driving
anchorage-independent growth by performing soft agar assay. The observation that
sphere formation was enhanced upon loss of Smad4 added to the overall picture and
supported the previous finding of facilitated dissemination and colony formation in
distant metastasis.
In our in vitro and in vivo approaches covering different genetic backgrounds, we
scrutinized the importance of Smad4 in Kras-driven PDAC. Combining all the data
gathered in various models, we provided evidence for increased PDAC aggressiveness in
Smad4 deficiency based on shortened lifespan and enhanced migrative potential com-
bined with excessive fibrosis, ECM modulation, facilitated detaching and promoted dis-
semination contributing to improved metastasis formation. Importantly, we identified
nuclear NFATc1/Smad3/cJun transcription factor assembly exclusively upon loss of
Smad4. Our RNAseq studies revealed potential involvement of NFATc1/Smad3/cJun
transcription complexes in driving the expression of unfavorable prognostic genes in
PDAC, alteration of tumor microenvironment, and tumor cell morphology.
4.2 Smad4 status determines chemotherapeutic
response in PDAC
Chemotherapeutic treatment of PDAC has proven to be a challenge due to minor tumor
vascularization, lack of effective immune response and dense fibrotic stroma (Young
et al., 2018). Since decades, Gemcitabine-based chemotherapy has been exploited for
the treatment of PDAC and still prevails against the FOLFIRINOX regime because of
enhanced patient tolerability despite relatively reduced efficacy (Conroy et al., 2011;
Braiteh et al., 2017; Muranaka et al., 2017). Gemcitabine’s toxicity is mediated by




In our experimental setup, we tested Gemcitabine response in the context of serum-
supplemented cultivation medium to ensure full proliferative capacity of Smad4 WT
and k.o. cell clones. Indeed, we demonstrated more than twofold increase of Gemcita-
bine IC50 in NKC-II, KPC Bl6 and Panc-1 cells upon Smad4 deficiency, respectively.
Importantly, this implicated enhanced Gemcitabine tolerance of Smad4 k.o. cells de-
spite unaltered proliferative capacity in three different Kras-driven PDAC cell lines
















Figure 30 Smad4 deficiency interferes with Gemcitabine toxicity. Gem-
citabine metabolism relies on several metabolizing steps from the
prodrug (dFdC) to the nucleoside analog dFdCTP. Smad4-deficient
PDAC cells demonstrate altered regulation by Trametinib and NFATc1
silencing of the indicated enzymes in green, thus intervening with Gem-
citabine metabolism on three different spots. Modified from Tanaka
et al. (2010).
Additionally, we aimed to figure out if Smad4-dependent chemotherapy tolerance is a
mechanism universally applicable for nucleoside analogs or specific for Gemcitabine.
Therefore, we employed AraC, also known as cytarabine, for chemotherapeutic toler-
ance studies. We hereby confirmed the same tendency of increased AraC response in
Smad4 WT Panc-1 and NKC-II cells compared to their corresponding Smad4-depleted
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counterparts, respectively. According to Li et al. (2008), the prodrugs share similar
chemical structures, metabolic pathways and mechanisms of action, suggesting Smad4-
dependent regulation of a common regulator. Our RNAseq analysis provided insight in
the regulation of genes associated with Gemcitabine and AraC metabolism by identify-
ing four genes that are are differentially regulated by Trametinib and NFATc1 silencing
upon loss of Smad4 [Figure 30]. Thus, Cda, Dctd, Rrm1, and Rrm2 are not only po-
tentially regulated by NFATc1/Smad3/cJun transcription complexes, but are proposed
mediators of increased Gemcitabine tolerance in Smad4 deficiency.
Cda plays a pivotal role in detoxifying Gemcitabine, as it converts 90 % of the Gemcita-
bine or 2’,2’-difluoro 2’-deoxycytidine (dFdC) to 2’2’-difluoro 2’-deoxyuridine (dFdU)
which can be released from the cell (Neff & Blau, 1996; Eliopoulos et al., 1998; Ueno
et al., 2007). Samulitis et al. (2015) described Cda upregulation upon induced Gemcita-
bine resistance which was accompanied by increased invasive and metastatic potential
of PDAC cells. Dctd deaminates Gemcitabine monophosphate (dFdCMP) to 2’2’-
difluoro 2’-deoxyuridine monophosphate (dFdUMP) but is inhibited by Gemcitabine
triphosphate (dFdCTP), the final metabolite for DNA implementation (Heinemann
et al., 1992; Mini et al., 2006). In contrast, Rrm1 and Rrm2 do not interfere with
Gemcitabine metabolism, but convert ribonucleosides to deoxyribonucleoside triphos-
phates which compete with dFdCTP in DNA strand assembly (Cory & Sato, 1983;
Nakano et al., 2007). In fact, Shukla et al. (2017) revealed that deoxycytidine nu-
cleotide levels positively correlate with Gemcitabine IC50 in a panel of 15 PDAC cell
lines. Rrm1 was identified as a mediator of induced Gemcitabine resistance in a murine
in vivo model of colon cancer as well as in vitro in pancreatic cancer (Nakahira et al.,
2007). Accordingly, various papers described Rrm1 as a predictive marker of Gemci-
tabine response in non-small-cell lung carcinoma (Rosell et al., 2004; Davidson et al.,
2004; Bepler et al., 2006) and breast cancer (Rha et al., 2007). However, in pancre-
atic cancer neither Dctd nor Rrm1 showed any prognostic value (Elander et al., 2018).
Rajabpour et al. (2017) demonstrated suppressed downregulation of Rrm1 and Cda
by miR-608 in pancreatic cancer, resulting in Gemcitabine resistance. Besides its role
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in promoting Gemcitabine tolerance (Chen et al., 2018), Rrm2 was implicated in pro-
moting malignant transformation and invasion (Fan et al., 1996; Zhou et al., 1998).
Clinical studies on Rrm2 mRNA levels demonstrated inverse correlation with overall
survival of Gemcitabine-treated PDAC patients (Itoi et al., 2007; Fujita et al., 2010).
We summarize that Gemcitabine resistance occurred in various cancer cell types and
mostly relied on the misregulation of more than one gene mediating the pyrimidine
nucleoside analog’s toxicity. Thus, differential regulation of Cda, Dctd, Rrm1, and
Rrm2 interfered in three different ways with Gemcitabine’s toxicity and the interplay
of these proteins could convey additional oncogenic potential.
Among the four genes implicated in mediating Gemcitabine toxicity, loss of Smad4 led
to significant upregulation of Rrm1 and Rrm2, respectively. This was in agreement with
findings from our RNAseq analysis, where we identified potential NFATc1/Smad3/cJun
targets and unraveled their function via GO analysis. Importantly, the top hits were
associated with deoxyribonucleotide and deoxyribonucleoside metabolism and synthe-
sis, substantiating the strong potential of Smad4-deficient PDAC cells in counteracting
nucleoside analog-based chemotherapeutic agents. In line with findings of Shukla et al.
(2017), we observed strong induction of pyrimidine pathway. Santana-Codina et al.
(2018) revealed that excess supply of deoxyribonucleosides prevented cell death in
Kras-driven PDAC cells. Increased supply of nucleotides in addition to upregulation
of DNA replication and cell cycle propagation would suggest an increased proliferation
rate in Smad4-deficient cells. Surprisingly, we did not observe any difference in cel-
lular growth comparing Smad4 k.o. cells to their Smad4 WT counterparts. Possible
explanations include that other nutritients and elements crucial for sufficient PDAC
cell growth were limited and thus restrict proliferation to the level observed in Smad4
WT cells.
It is important to note that induction of Gemcitabine resistance in KPC Bl6 cells
by sustained exposure to the prodrug did not result in alterations of Smad4 expres-
sion, although induced resistance also relied on excessive Rrm1 and Rrm2 upregulation,
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respectively. This suggested that although Smad4 deficiency drives enhanced Gemcita-
bine tolerance in vitro, acquired Gemcitabine resistance is not mediated via modulation
of Smad4 levels by genetic or epigenetic mechanisms although similarly employing en-
hanced supply of competing nucleotides. In conclusion, Smad4 deficiency provided an
increased resistence against nucleoside analogs in general, but the exact mode of action
remains elusive.
In contrast to systemic chemotherapy approaches using nucleoside analogs, Mek1/2
inhibition by Trametinib or UO126 met the criteria for targeted cancer therapy. In our
experiments, serum-supplemented medium was not crucial to identify alterations in
cell viability caused by the tyrosine kinase inhibitor Trametinib. Instead, Trametinib
response relied on growth factors like TGFβ, which was comprised in undefined doses
in FBS. As we observed increased Trametinib effects in both NKC-II clones when
cultivated in TGFβ-enriched medium, we concluded that TGFβ is the driving force in
mediating Mek1/2 inhibition in cultivation medium.
Importantly, we introduced Mek inhibitors that demonstrated the potential to disrupt
nuclear NFATc1/Smad3/cJun complex formation in vitro. Both UO126 and Trame-
tinib proved to successfully interfere with the transcription complex assembly, thus dis-
rupting the promotion of oncogenic gene signature and establishing a therapeutic win-
dow for systemic chemotherapy approaches. Kretzschmar et al. (1999) introduced Erk
as an important regulator of Smad3 activity through linker domain phosphorylation,
while Yang et al. (2003) confirmed that UO126 treatment with subsequent Erk dephos-
phorylation leads to partial reduction of TGFβ responsiveness. Together with the re-
sults of Sekimoto et al. (2007) underlining the importance of different Smad3 phospho-
rylation sites in defining the transcriptional targets, we proposed Mek inhibition with
downstream loss of Erk phosphorylation as a tool to (i) disrupt NFATc1/Smad3/cJun




The exact mechanism on how Mek inhibition disrupted nuclear NFATc1/Smad3/cJun
complexes remains elusive. Knock down experiments with subsequent co-IP revealed
complex disruption upon silencing of either cJun or Smad3. In addition, Smad3/cJun
interaction studies in Nfatc1-depleted PDAC cells demonstrated promotion of nuclear
Smad3/cJun complexes by Smad4 silencing in the absence of Nfatc1. However, if
NFATc1 expression contributed to Smad3/cJun complex stability or further promoted
Smad3/cJun assembly was not addressed in this study. The observed Smad4 depen-
dency suggested involvement of the carboxy-terminal MH2 domain of Smad3 in cJun
binding, which needs to be confirmed in further experiments.
Mek inhibitors have been shown to reduce cJun binding to DNA (Adiseshaiah et al.,
2008) and interfere with its expression levels (Favata et al., 1998). This expands the
effect of Mek inhibition on cell growth, survival, adhesion, and differentiation to cJun-
mediated proliferation and apoptosis (Rožanc et al., 2018). However, cJun can either
suppress or promote tumor development, depending on the cell type, tumor stage,
differentiation, and the genetic background (Eferl & Wagner, 2003). In colon cancer,
cJun drives the expression of matrix metalloproteinase 9 (Mmp9) thus accelerating
invasive potential of cells (Loesch et al., 2010). This is in agreement with Cai et al.
(2017) describing the importance of cJun in EMT phenotype and acquisition of motil-
ity potential in pancreatic cancer. As the inflammatory transcription factor NFATc1
modulates Mmp13 expression (Baumgart et al., 2014), we suggest synergistic coopera-
tivity of both transcriptional modulators in an inflammatory tumor microenvironment.
This is in agreement with Chen et al. (2015), demonstrating a huge overlap of AP-1
and NFATc1-regulated gene signatures in PDAC. Indeed, cJun was portrayed as a
pro-inflammatory factor in the pancreas (Cobo et al., 2018), while Qiao et al. (2016)
emphasized the role of cJun in triggering inflammation-induced breast cancer progres-
sion. Importantly, Ramsdale et al. (2015) established the link between cJun-driven
mesenchymal gene signatures and consequential association with increased drug resis-
tance in melanoma cells.
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Importantly, Smad4-deficient PDAC cells were more susceptible to Mek inhibition com-
pared to their Smad4 WT expressing counterparts. The Mek/Erk signaling cascade
is one of the four pathways downstream of Kras (Collisson et al., 2012) which show a
high degree of variability and preferred signaling in different contexts (Nussinov et al.,
2015). In PDAC, the Mek pathway is associated with neoplastic alterations in PDAC
(Collisson et al., 2012). Our data add up to findings of Santana-Codina et al. (2018),
elucidating the mechanism of maintaining nucleotide pools as a specific metabolic pro-
file in Kras dependency. We hypothesize that Smad4 deficiency favors induction of
Mapk-dependent signaling by oncogenic Kras, leading to Myc upregulation and pro-
motion of the non-oxidative pentose phosphate pathway resulting in enforced nucleotide
biosynthesis (Santana-Codina et al., 2018). Importantly, Santana-Codina et al. (2018)
suggested Mek inhibition as an effective tool to antagonize pyrimidine biosynthesis,
which we support in the context of Smad4 deficiency. We hypothesize that Smad4-
depleted cells as opposed to Smad4 WT promote oncogenic signaling via Mek, but the
mechanism behind increased Mek dependency of Smad4-deficient PDAC in the context
of oncogenic Kras activation remains elusive.
Kawaguchi et al. (2018) introduced the clinical potential of combinatorial Gemcitabine
and Trametinib treatment in patient-derived orthotopic xenograft models, resulting in
significantly reduced tumor volume in nude mice. However, clinical studies with this
treatment regiment (NCT1 231 581/phase 2) in metastatic PDAC failed to proof signif-
icant supremacy in overall survival compared to Gemcitabine combined with placebo
therapy (Infante et al., 2014). This discrepancy between in vitro mouse models and
the human situation can at least partially be explained by the use of immunodeficient
mice in the patient-derived xenograft studies. In our in vitro studies, we observed addi-
tive chemotherapeutic response of Gemcitabine and Trametinib exclusively in Smad4-
deficient PDAC cells. Initially Gemcitabine-tolerant Smad4-depleted PDAC cells be-
come sensitized by supplementary Trametinib treatment, suggesting that patient strat-
ification according to Smad4 status prior to combined Gemcitabine/Trametinib treat-
ment might be beneficial for the survival of Smad4-deficient PDAC patients. This
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is supported by our RNAseq data demonstrating approximation of gene signature in
Trametinib-treated TGFβ-activated Smad4-deficient cells to corresponding Smad4 WT
cells. This overall alteration in gene expression pattern does not suggest Gemcitabine
hypersensitivity of NKC-II Smad4 k.o. cells subsequent to Trametinib administration,
but rather resensitization to the level that is observed in associated Smad4 WT clones.
Thus, we demonstrated that Trametinib administration influences the global gene ex-
pression pattern and in detail leads to resensitization to Gemcitabine by interfering
with its antitumoral activity by influencing both its metabolism and incorporation
into the replicating DNA strand.
However, maintenance of nucleotide biosynthesis is one mechanism to resist against
Mek inhibition (Santana-Codina et al., 2018). Trametinib treatment provokes feed-
back activation of Ras, thus resulting in no persistent Mek inhibition (Dai et al., 2019).
Interestingly, Dai et al. (2019) introduced zoledronic acid as a food and drug adminis-
tration (FDA)-approved tool to overcome Trametinib resistance. Zoledronic acid was
already exploited in patient-derived orthotopic xenograft studies using human PDAC
samples and could effectively reduce metastatic burden in combination with Gemcita-
bine (Hiroshima et al., 2015). As we observed increased invasive behavior upon Smad4
deficiency in PDAC cells in vitro and enhanced metastatic burden upon homozygous
loss of Smad4 in vivo, additional zoledronic acid could further restrict tumor cell dis-
semination combined with the cytostatic and cytotoxic properties of Trametinib and
Gemcitabine, respectively. Importantly, Singh et al. (2011) scrutinized the potential
of zoledronic acid to disrupt NFAT stabilization. Thus, combination of these three
drugs could target NFATc1/Smad3/cJun complexes in Smad4 deficiency by interfer-
ing with both NFATc1 and cJun, while keeping TGFβ signaling intact to enable the
reestablishment of tumor-suppressive gene signatures.
Drug sensitivity studies in Smad4 WT and k.o. clones focused on Mek inhibitors and
nucleoside analogs, respectively. First of all, we demonstrated disruption of nuclear
NFATc1/Smad3/cJun complexes upon Mek inhibition by UO126 and Trametinib,
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respectively. This was associated with increased Trametinib sensitivity of Smad4-
depleted PDAC cells in vitro. In contrast, we revealed increased tolerance against
nucleoside analogs in Smad4 deficiency as opposed to Smad4 WT PDAC. RNAseq
analyses scrutinized the expression of enzymes involved in Gemcitabine metabolism
and incorporation into the DNA strand, resulting in the elucidation of four genes po-
tentially involved in mediating selective Gemcitabine tolerance upon loss of Smad4.
Both NFATc1 silencing and Trametinib administration led to downregulated expres-
sion levels of respective targets, thus resulting in increased susceptibility of Trametinib-
treated Smad4-deficient PDAC cells against Gemcitabine. This mode of action sug-
gests involvement of nuclear NFATc1/Smad3/cJun complexes in mediating increased
Gemcitabine tolerance of Smad4-depleted PDAC.
4.3 Concluding remarks
Until today, PDAC remains a highly lethal disease due to extraordinary cancer cell
plasticity and tumor heterogeneity. Frequent alterations in PDAC comprise oncogenic
Kras activation (90 %) and loss of the tumor suppressor Smad4 in 55 % of all patients.
The frequency of Smad4 alteration makes it an interesting target to exploit Smad4-
associated PDAC vulnerabilities for novel targeted therapeutic approaches. Smad4
is an important mediator of TGFβ-mediated tumor suppression that restrains tu-
mor growth and progression. Smad4 depletion transforms tumor-suppressive TGFβ
signaling to aggressive and invasive gene signatures accelerating disease progression,
metastasis formation and thus resulting in dismal prognosis. In this study, we aimed
to decipher how Smad3-mediated transcription is hijacked for fulminant oncogenic sig-
naling. In detail, the mechanistic and functional consequences of Smad4 deficiency are















Figure 31 Trametinib targets oncogenic NFATc1/Smad3/cJun com-
plexes in Smad4-deficient PDAC. Our current working model
suggests a novel therapeutic approach for the large subgroup of
Smad4-depleted PDAC patients. Loss of Smad4 favors nuclear
NFATc1/Smad3/cJun transcription factor assembly promoting the ex-
pression of oncogenic gene signatures resulting in enhanced invasive-
ness and metastasis formation by modulation of tumor microenviron-
ment and tumor cell morphology. Additionally, upregulation of nu-
cleotide metabolism impairs Gemcitabine-based chemotherapy, lead-
ing together with fostered expression of proliferative genes to reduced
survival of Smad4-deficient PDAC patients. Trametinib administra-
tion disrupts nuclear NFATc1/Smad3/cJun complexes, diminishes the
expression of unfavorable prognostic genes in PDAC and restores Gem-
citabine susceptibility for improved chemotherapeutic response.
In this work, we described the assembly of NFATc1/Smad3/cJun complexes in Smad4-
deficient PDAC in the context of oncogenic Kras activation. RNAseq analyses em-
ployed to disclose potential signatures of this transcription complex revealed the piv-
otal role of NFATc1/Smad3/cJun-driven transcription for the expression of unfavorable
prognostic genes in PDAC, thus providing a potential link of NFATc1/Smad3/cJun
complexes and dismal outcome of Smad4-deficient PDAC patients. Morphological
alterations of Smad4-deficient PDAC cells associated with increased dissemination
capacity observed in vitro and in vivo were retraced to genes differentially regu-
lated by NFATc1/Smad3/cJun complexes. Importantly, invasion and migration po-
tential was further driven by modulating the composition of the tumor microenviron-
ment, facilitating metastasis formation in Smad4-deficient PDAC. Thus, we suggest
that NFATc1/Smad3/cJun-regulated transcription is the main driver of the tumor-
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promoting signatures of Smad4-deficient PDAC. Additionally, we revealed increased
Gemcitabine tolerance in Smad4-depleted PDAC cells which is established by enzymes
potentially regulated by NFATc1/Smad3/cJun complexes. Disrupting the nuclear tran-
scription factor complex by Trametinib treatment resulted in decrease of both unfa-
vorable prognostic signatures and the expression of genes interfering with Gemcitabine
cytotoxicity. Importantly, NFATc1/Smad3/cJun complex disassembly was significantly
linked with a favorable prognosis and increased Gemcitabine sensitivity, offering a ther-
apeutic approach in Smad4 deficiency.
The assertion of Trametinib-induced Gemcitabine resensitization of Smad4-deficient
PDAC preferably needs to be tested in Smad4-depleted GEMMs as well as patient-
derived xenografts of SMAD4-deficient human PDAC. Both approaches aim at study-
ing drug responses in three-dimensional tumors embedded in their respective tumor
environment. This can be supplemented by short-term drug response studies of PDAC
patient biopsies cultivated on media-soaked gelatin sponge (Centenera et al., 2013,
2018), enabling us to investigate the influence of therapeutic regimes directly at bulk
tumor pieces containing PDAC cells, ECM, and intact tumor stroma.
We hereby propose that in future, patient stratification according to their respective
SMAD4 status offers a new targeted approach in PDAC therapy. We conclude from our
studies that Trametinib administration is beneficial for treatment of SMAD4-deficient




Abdollah, S., Macias-Silva, M., Tsukazaki, T., Hayashi, H., Attisano, L., & Wrana, J. L.
(1997). TbetaRI Phosphorylation of Smad2 on Ser465 and Ser467 Is Required for
Smad2-Smad4 Complex Formation and Signaling. Journal of Biological Chemistry,
272(44), 27678–27685.
Abe, H., Kikuchi, S., Hayakawa, K., Iida, T., Nagahashi, N., Maeda, K., Sakamoto,
J., Matsumoto, N., Miura, T., Matsumura, K., Seki, N., Inaba, T., Kawasaki, H.,
Yamaguchi, T., Kakefuda, R., Nanayama, T., Kurachi, H., Hori, Y., Yoshida, T.,
Kakegawa, J., Watanabe, Y., Gilmartin, A. G., Richter, M. C., Moss, K. G., &
Laquerre, S. G. (2011). Discovery of a Highly Potent and Selective MEK Inhibitor:
GSK1120212 (JTP-74057 DMSO Solvate). ACS medicinal chemistry letters, 2(4),
320–324.
Adamska, A., Domenichini, A., & Falasca, M. (2017). Pancreatic Ductal Adenocarci-
noma: Current and Evolving Therapies. International Journal of Molecular Sciences,
18(7).
Adiseshaiah, P., Li, J., Vaz, M., Kalvakolanu, D. V., & Reddy, S. P. (2008). ERK
signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter.
Biochemical and Biophysical Research Communications, 371(2), 304–308.
Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., Chilton,
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Gallego, L., Dubus, P., Sandgren, E. P., & Barbacid, M. (2007). Chronic Pancreatitis
Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes
in Adult Mice. Cancer Cell, (11 (3)), 291–302.
Hahn, S. & Kern, S. E. (1995). Molecular genetics of exocrine pancreatic neoplasms.
Surgical Clinics of North America, (75 (5)), 857–869.
Hahn, S. A., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Schutte, M., Rozenblum,
E., Seymour, A. B., Weinstein, C. L., Yeo, C. J., Hruban, R. H., & Kern, S. E.




Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum,
E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., & Kern, S. E. (1996b).
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science
(New York, N.Y.), 271(5247), 350–353.
Hanafusa, H., Ninomiya-Tsuji, J., Masuyama, N., Nishita, M., Fujisawa, J., Shibuya,
H., Matsumoto, K., & Nishida, E. (1999). Involvement of the p38 mitogen-activated
protein kinase pathway in transforming growth factor-beta-induced gene expression.
The Journal of Biological Chemistry, 274(38), 27161–27167.
Hartsough, M. T. & Mulder, K. M. (1995). Transforming growth factor beta activation
of p44mapk in proliferating cultures of epithelial cells. The Journal of Biological
Chemistry, 270(13), 7117–7124.
Hasselluhn, M. C., Schmidt, G. E., Ellenrieder, V., Johnsen, S. A., & Hessmann, E. (in
revision). Aberrant NFATc1 signaling counteracts TGFbeta-mediated growth arrest
and apoptosis induction in pancreatic cancer progression. Cell Death and Disease.
Heinemann, V., Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plun-
kett, W. (1992). Cellular elimination of 2’,2’-difluorodeoxycytidine 5’-triphosphate:
a mechanism of self-potentiation. Cancer Research, 52(3), 533–539.
Heldin, C. H., Miyazono, K., & ten Dijke, P. (1997). TGF-beta signalling from cell
membrane to nucleus through SMAD proteins. Nature, 390(6659), 465–471.
Hessmann, E., Zhang, J.-S., Chen, N.-M., Hasselluhn, M., Liou, G.-Y., Storz, P.,
Ellenrieder, V., Billadeau, D. D., & Koenig, A. (2016). NFATc4 Regulates Sox9
Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. Stem
Cells International, 2016, 5272498.
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A.,
Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., Kawaguchi, Y., Johann, D.,
Liotta, L. A., Crawford, H. C., Putt, M. E., Jacks, T., Wright, C. V. E., Hruban,
116
References
R. H., Lowy, A. M., & Tuveson, D. A. (2003). Preinvasive and invasive ductal
pancreatic cancer and its early detection in the mouse. Cancer Cell, (4 (6)), 437–
450.
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T., Hruban, R. H.,
Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005). Trp53r172h and KrasG12d co-
operate to promote chromosomal instability and widely metastatic pancreatic ductal
adenocarcinoma in mice. Cancer Cell, (7 (5)), 469–483.
Hiroshima, Y., Maawy, A. A., Katz, M. H. G., Fleming, J. B., Bouvet, M., Endo,
I., & Hoffman, R. M. (2015). Selective efficacy of zoledronic acid on metastasis
in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human
pancreatic cancer. Journal of Surgical Oncology, 111(3), 311–315.
Hocevar, B. A., Brown, T. L., & Howe, P. H. (1999). TGF-beta induces fibronectin syn-
thesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway.
The EMBO journal, 18(5), 1345–1356.
Hosoda, W., Chianchiano, P., Griffin, J. F., Pittman, M. E., Brosens, L. A., Noë,
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Sjöblom, T., Edqvist, P.-H., Djureinovic, D., Micke, P., Lindskog, C., Mardinoglu,
A., & Ponten, F. (2017). A pathology atlas of the human cancer transcriptome.
Science (New York, N.Y.), 357(6352).
UniProt Consortium, T. (2018). UniProt: the universal protein knowledgebase. Nucleic
Acids Research, 46(5), 2699–2699.
Vigil, D., Martin, T. D., Williams, F., Yeh, J. J., Campbell, S. L., & Der, C. J. (2010).
Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide
exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-
independent mechanisms. The Journal of Biological Chemistry, 285(45), 34729–
34740.
Vincent, D. F., Gout, J., Chuvin, N., Arfi, V., Pommier, R. M., Bertolino, P., Jon-
ckheere, N., Ripoche, D., Kaniewski, B., Martel, S., Langlois, J.-B., Goddard-Léon,
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Smad4 deficiency does not interfere with proliferation
of PDAC cells
To confirm that loss of Smad4 in PDAC cells is not associated with alterations in pro-
liferative capacity, we performed cell counting experiments in murine NKC-II and KPC
Bl6 as well as human Panc-1 clones [Figure 14 B, 32]. In all established PDAC Smad4
k.o. clones, we demonstrated maintained proliferation levels irrespective of Smad4 sta-
tus. Thus, we conclude that loss of Smad4 does not influence cellular growth.
Figure 32 Proliferative capacity is not influenced by Smad4 status of
PDAC cells. Murine KPC Bl6 and human Panc-1 clones were con-
ducted to cell counting experiments to record proliferation over 6 d in
FBS-supplemented medium. Subsequent to seeding 20 000 cells in trip-
licates, cells were trypsinized, counted and seeded again every second
day (n = 3, respectively).
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Chemotherapeutic response depends on Smad4 status
of PDAC cells
Chemotherapeutic response to nucleoside analogs was tested in 72 h MTT approaches
with cells cultivated in FBS-supplemented cultivation medium [Figure 28 A, 33]. Through-
out all established Smad4 clones, we observed significantly increased tolerance against
AraC and Gemcitabine upon loss of Smad4, respectively. This suggests that Smad4







Figure 33 Smad4 deficiency enhances Gemcitabine and AraC tolerance
in PDAC cells. MTT experiments were conducted in quintuplicates
in a 96 well plate. Subsequent to 72 h incubation with the respective
nucleoside analog, IC50 of independent experiments was calculated.
A Murine KPC Bl6 (n = 3) and human Panc-1 clones (n = 5) were
tested for Gemcitabine tolerance in increasing concentrations. B AraC




Induced Gemcitabine resistance is not associated with
Smad4 silencing
In another approach, we aimed to reveal whether Gemcitabine resistancy accomplished
by consequent incubation in Gemcitabine-containing cultivation medium is achieved by



























Figure 34 Induced Gemcitabine tolerance in KPC Bl6 cells is not me-
diated by Smad4 silencing. KPC Bl6 cells were cultivated with
increasing concentrations of Gemcitabine until reaching tolerance for
200 nM Gemcitabine. A Protein samples from KPC Bl6 control and
Gemcitabine-resistant cells were conducted to western blot analysis to
check for variations in Smad4 expression. B Transcription levels of
Smad4, Nfatc1, Smad3 and cJun were checked subsequent to induced
Gemcitabine tolerance via qRT-PCR. C Expression of previously iden-




centrations of Gemcitabine, starting from 5 nM. Upon reaching tolerance for 200 nM,
cells were further cultivated in medium containing this Gemcitabine concentration.
RNA and protein of Gemcitabine-resistant and control KPC Bl6 cells were conducted
to western blot and qRT-PCR studies [Figure 34 A+B]. Induced Gemcitabine resis-
tance was associated with alterations in Nfatc1, Smad3 and cJun levels, respectively,
but did not interfere with Smad4 protein and mRNA expression. Interestingly, Smad3
mRNA level were not induced upon Gemcitabine resistance despite strong increase of
respective protein expression.
Although induced Gemcitabine restance was not mediated via Smad4 silencing, we
intended to check if expression levels of previously identified enzymes were affected
in the acquisition of Gemcitabine tolerance [Figure 34 C]. Interestingly, we detected
the same strong involvement of Rrm1 and Rrm2 enzymes, and to a lesser extend,
Dctd. These findings suggest that provision of an increased nucleotide supply is a
common strategy to escape Gemcitabine-mediated cytotoxicity by direct competition
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